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The mitochondrial genome is a small, plasmid-like chromosome which encodes only 
13 protein subunits yet is vital for electron transport in the mitochondrion and, therefore, vital 
for the existence of multicellular life.  Despite this importance, mitochondrial DNA 
(mtDNA) is found in one of the least-protected areas of the cell, and is exposed to high 
concentrations of intracellular reactive oxygen species (ROS) and threat from exogenous 
substances and pathogens.  Until recently, the quality control mechanisms that ensured the 
stability of the nuclear genome were thought to be minimal in the mitochondria.  However, a 
vast network of mechanisms has been discovered that repair mtDNA lesions, replace and 
recycle mitochondrial chromosomes, and conduct alternate RNA processing for previously 
undescribed mitochondrial proteins.  New mtDNA/RNA-dependent signaling pathways 
reveal a mostly undiscovered biochemical landscape in which the mitochondria interface 
with their host cells/organisms.  As the myriad ways in which the function of the 
mitochondrial genome can affect human health have become increasingly apparent, the use 
of mitogenomic biomarkers (such as copy number and heteroplasmy) as toxicological 
endpoints has become more widely accepted.  The objective of this dissertation was to 
investigate the role of mitochondrial genotoxicity in exacerbation and susceptibility to 




(BECs) were collected from human donors, healthy and those with chronic inflammatory 
lung diseases, and grown through multiple passages in serum-free culture.  Disease groups 
were compared to healthy cells for mitogenomic markers, including expression of mtDNA 
genes, ultradeep sequencing for heteroplasmic frequency and mutant alleles, mtDNA lesions, 
and processing of polycistronic mtRNA using Nanostring probes.  These results were 
compared to functional endpoints, including oxygen consumption rate, mitophagy, and cell 
viability/apoptosis, to determine whether observed mitogenomic stress had effects on 
epithelial cell function.  The results of these studies indicated that severe chronic lung 
inflammation associated with fatal asthma and cystic fibrosis can cause impaired expression 
of mitochondrial genes, perhaps due to failed mtRNA processing.  Similar endpoints were 
also examined following in vitro exposure of healthy BECs to nanomaterials, to examine 
acute genotoxic effects on mtDNA.  Nanoparticle exposures had little mitogenomic effect, 
though carbon nanotubes did significantly decrease mtDNA expression, secondary to 
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CHAPTER 1: INTRODUCTION 
 
Lung Inflammation and mtDNA Overview 
Inflammatory lung diseases are among the leading causes of death in the developed 
world.  According to the Centers for Disease Control (CDC), over 160,000 deaths were 
reported in the US in 2019 due to chronic lower respiratory diseases, making it the third 
leading non-injury cause of death after heart disease and cancer1.  Due largely to the 
prolonged nature and expense of living with these diseases, the economic cost of chronic 
lung disease is substantial.  In the US, over $100 billion in combined healthcare and 
economic costs (including absenteeism) can be attributed to asthma2 and chronic obstructive 
pulmonary disease (COPD)3 alone, afflicting 22.6 and 12 million Americans, respectively.  
Other forms of chronic inflammatory lung disease, such as cystic fibrosis (CF)4, interstitial 
lung disease (e.g. idiopathic pulmonary fibrosis (IPF))5, and tuberculosis (TB)6, while not as 
widespread, nonetheless pose major world health problems without effective treatment 
options. 
Despite extensive global efforts, many questions remain regarding the pathogenesis 
and lasting impairment of lung function from many of these lung conditions.7  Chronic 
inflammatory lung diseases often remain highly detrimental even when later controlled by 
inhaled corticosteroids or β2 adrenergic receptor agonists8-10.  Identification of the 




complicated by exposure to air pollution11-13.  Inhaled pollutants are ubiquitous in developed 
countries, and the myriad ways in which these chemicals and their secondary metabolites 
interact with the immune system and epithelium of the lungs convolute the etiology of human 
lung disease.  Additionally, the long-term impact of human exposure to entirely new classes 
of inhaled pollutants, such as nanomaterials, has yet to be fully characterized14-16. 
Consequently, there exists a need for novel approaches to diagnosing and treating 
chronic inflammatory lung diseases, and further exploration of the mechanisms which govern 
their long-term health effects even after treatment.  In this dissertation, I explore the 
possibility that mtDNA damage and heteroplasmy may be important contributors to the long-
term health effects of oxidative lung injury, through a variety of mechanisms including 
impaired electron transport, intracellular signaling, the release of extracellular damage-
associated molecular patterns (DAMPs), and apoptosis (see an overview of these processes in 
Figure 1.1). 
While the existence and basic function of the mitochondrial genome has been known 
for decades, its role in human disease (beyond dysfunctional mutant variants17) has only 
recently been investigated18-21.  This is due in large part to recent technological 
advancements, such as ultradeep sequencing and extracellular flux assay, which make it 
possible to measure subtle changes in mitochondrial heteroplasmy, allele frequency, copy 
number, and electron transport.  Our modern understanding of mtDNA has enabled us to 
consider mitogenomic endpoints as biomarkers of disease and/or toxicity, and potentially as 





Mitochondria in Mammalian Cells 
Mitochondria are essential organelles for nearly every eukaryotic cell and are 
responsible for the majority of ATP production in these cells.  Oxidative phosphorylation 
(OXPHOS) within the mitochondrial inner membrane utilizes Kreb’s cycle and glycolysis 
products (NADH and FADH2) to form a proton gradient.  The energy generated by releasing 
this proton gradient through the ATPase channel permits phosphorylation of ADP, thereby 
earning the mitochondrion’s nickname “powerhouse of the cell”.  While this is certainly its 
most well-known function, mitochondria serve several other critical roles in the cell as well.   
B-cell lymphoma 2 (BCL2) is a well-established inhibitor of apoptosis found in the 
mitochondrial outer membrane where it protects the inner membrane from pro-apoptotic bcl-
2-associated X protein (BAX)22.  BAX is normally a cytosolic protein, but translocates to the 
mitochondrial membrane following a conformational change induced by BH3 interacting-
domain death agonist (BID) or other BH3-domain apoptosis signaling molecules.  Unless 
bound and inactivated by BCL2, BAX then signals voltage-dependent anion channels 
(VDACs) in the inner membrane to open, decreases mitochondrial membrane potential 
(MMP), and halts electron transport.  MMP refers to the permeability of the mitochondrial 
inner membrane, which is normally impermeable to permit the generation of a proton 
gradient.  A loss of MMP, either by redox stress or signaling molecules, causes the release of 
second mitochondria-derived activator of caspases (SMAC, also known as DIABLO) from 
the matrix into the cytosol23, where it can bind to (and inactivate) the anti-apoptotic factor X-
linked inhibitor of apoptosis protein (XIAP).  XIAP inhibits the activity of several pro-
apoptotic proteins, including caspases 3, 7, and 9, so mitochondrial membrane damage is, 




significantly more complex over the last decade and forms the basis for the intrinsic pathway 
for apoptosis. 
Another critical function of mitochondria characterized more recently is calcium 
signaling.  Calcium flux is handled by the mitochondrial calcium uniporter (mCU) across the 
inner membrane, maintaining the relatively high (up to 100s of uM) calcium concentrations 
in the matrix required for dehydrogenase activity25.  While cytosolic Ca+2 concentrations are 
primarily maintained by the endoplasmic reticulum, the mitochondrion is known to have a 
similar role in removing excess calcium through active transport26.  An overload of Ca+2 in 
the matrix can trigger opening of the permeability transition pore (PTP), a “megachannel” 
protein spanning the inner and outer membranes which quickly releases SMAC and 
cytochrome C from the matrix, inducing apoptosis through the intrinsic pathway. 
The Mitochondrial Genome 
Mitochondria are believed to be derived from Precambrian prokaryotic 
endosymbiotes and consequently retain a remnant of their own genome27.  The human 16.57 
kbp circular chromosome encodes 13 subunits of the electron transport chain (ETC), with at 
least one subunit from each of the ETC complexes except for complex II.  Additionally, 22 
mitochondria-specific tRNAs and 2 rRNA subunits are encoded by the mitochondrial 
genome, which enable transcription/translation processes that are separate from the cell’s 
nuclear genome.  While the majority of ETC complex subunits are coded by nuclear genes, 
the few that are encoded by the mitochondria are functionally essential for oxidative 
phosphorylation, and mutations in mitochondrial genes are often pathological28-29.  Such 




MELAS syndrome32, and cardiomyopathy33, among others34, and suggest that tissues which 
depend on high energy production (such as muscle) are highly susceptible.  Mutations in 
mtDNA have also been linked to neurodegenerative disorders, such as Alzheimer’s35 and 
Parkinson’s disease36. The importance of this small genome to eukaryotic function 
predictably results in many segments of mtDNA being highly conserved across multiple 
species37.  Mitochondria also typically contain multiple (8-12) copies of their genome and 
each cell contains hundreds or thousands of mitochondria, which results in each cell 
containing many thousands of mtDNA copies.  Not all these copies are 100% identical in 
sequence, which gives rise to the phenomenon of heteroplasmy.   
Heteroplasmy 
Heteroplasmy is the degree to which every mtDNA copy within a cell is identical at a 
given locus (Figure 1.2).  At most loci, over 99% of the mtDNA copies feature the major 
allele, and the cutoff for minor allele frequency considered “heteroplasmy” is not widely 
agreed-upon38.  “Microheteroplasmy” is a term often used to describe minor allele 
frequencies of up to 2%39, and it is only with recent developments in sequencing technology 
has microheteroplasmy been found to be a normal, homeostatic state in healthy cells40.  The 
term “heteroplasmy” today is most often used to refer to larger minor allele frequencies 
(usually 2-10% or higher) which are detectable through traditional PCR sequencing methods 
and are usually assumed necessary to have some pathophysiological effect on the cell or its 
ETC41.  Heteroplasmy has been known for many years to increase in cells with advancing 
age in humans42-43 (though this is less certain in shorter-lived organisms, such as mice44), and 
this gradual buildup of mitochondrial heteroplasmy is speculated to drive or contribute to 




Heteroplasmy (whether de novo or inherited) is ultimately the result of mutation, and 
as such, can be caused by many of the classical mutagenic agents of nuclear DNA.  Oxidative 
stress is a well-known inducer of mtDNA damage and is an especially important factor 
considering that the mitochondrion itself is the major source of redox radicals in the cell46.  
Enzymatic defenses, such as superoxide dismutase II (SOD2), are critical to controlling 
redox stress in the mitochondria, nonetheless, mtDNA damage due to endogenous radicals is 
known to occur47.  Other potentially genotoxic agents, such as exogenous chemicals48, UV 
phototoxicity49, and viral infections50, can likewise result in mtDNA damage, subsequent 
alterations in gene sequence, and eventual heteroplasmy.  Polymerase gamma (Polγ), the 
enzyme complex primarily responsible for mtDNA replication, is known to be capable of 
translesion synthesis (TLS)48, which can cause the development of permanent mtDNA 
mutations following damage.  Additionally, Polγ has been found to have a single base 
substitution error rate of 4.5x10-5 in the absence of proofreading exonucleases (decreasing to 
1.0x10-5 with proofreading)51.  While comparable to nuclear DNA polymerase error rates, the 
thousands of copies of mtDNA in each cell result in any given locus having a far higher 
probability of developing heteroplasmy with each mtDNA replication.  Another, more tissue-
dependent, factor which can induce heteroplasmy over time is inflammation52.  Organs and 
tissues that are subjected to frequent inflammatory stress (such as the lungs or intestine), 
particularly in cases of chronic inflammatory diseases, can create a microenvironment of 
endogenous redox radicals.  These endogenous chemicals can include hydrogen peroxide, 
nitric oxide, hydrogen sulfide, and superoxide radical, produced enzymatically by 




DNA is not immune to this challenge, and increased mtDNA damage in tissues exposed to 
chronic inflammatory stress has been found53-55. 
Repair of Mitochondrial DNA 
For many years, DNA repair mechanisms in the mitochondria were thought to be 
minimal and quality control was primarily accomplished through the recycling of poorly-
performing organelles.  While the mitochondria may not compare to the nucleus for DNA 
repair, many mechanisms for mtDNA repair have nevertheless been demonstrated and 
characterized56-57.   
Base excision repair (BER) in mitochondria is now well-established58.  BER is 
initiated by DNA glycosolases which cleave the N-glycosidic bond attaching a base to the 
phosphate backbone, leaving an apyrimidinic/apurinic site (AP site).  In humans, UNG1 
(uracil DNA glycosylase) and MUTYH (mutY DNA glycosulase) are active in the 
mitochondria and perform excision of erroneous uracil or adenine bases (respectively)59-60.  
Bifunctional glycosylases capable of excision of both single- and double-stranded lesions are 
also present in human mitochondria, including spliced variants of OGG1 (8-oxoguanine 
DNA glycosylase) and thymine glycol glycosylase (NTH1).  While the biomolecular 
pathways which enable BER in the mitochondrion are well-characterized, the initiating steps 
in detecting these mtDNA lesions are much less understood.  DNA glycosylases are recruited 
to the mitochondria in response to elevated redox stress, which may indicate the presence of 
signaling specific to mtDNA damage61. 
Nucleotide excision repair (NER) in mitochondria is not well characterized, though 




within mitochondria62.  These enzymes bind to mtDNA during redox stress, indicating a 
possibility that NER pathways may contribute to mtDNA repair.  The absence or dysfunction 
of these enzymes (as occurs in Cockayne Syndrome), has also been shown to increase 
deletion mutations in mtDNA induced by ultraviolet radiation63. 
Double strand breaks (DSB) are repaired by either homologous recombination or 
non-homologous end joining (NHEJ) in the nucleus64.  While there is little evidence for 
homologous recombination in mitochondria, recent investigations have revealed that 
mechanisms for NHEJ may be present65-67.  While classical NHEJ does not occur with 
mtDNA, microhomology-mediated end joining (MMEJ), mediated by PARP167, has been 
induced in mitochondrial extracts between oligonucleotides with nucleotide repeat ends68.  
As MMEJ results in nucleotide deletion (within the repeats), this may help to explain why 
most mtDNA deletions associated with human disease are flanked by short direct repeats69.  
When these repair mechanisms fail and the burden of induced mutations and 
heteroplasmy are sufficient to impair mitochondrial function (through misfolded subunits of 
ETC complexes, unprocessed mRNA transcripts, or through the production of non-
functioning tRNAs), the cell employs mitophagy to recycle the unusable mitochondria70.  
Mitophagy is the mechanism by which functionally-deficient portions of mitochondria are 
separated from usable portions and recruited to ubiquitin-mediated autophagy pathways for 
recycling.  When mitochondrial membrane potential (MMP) is low, following mitochondrial 
depolarization, PINK1 is stabilized on the outer membrane of these underperforming 
segments.  PINK1 phosphorylates Parkin, which, in turn phosphorylates ubiquitin, driving 
the ubiquitylation of mitochondrial membrane proteins.  The PINK1-labeled segments are 




phagophore can engulf these segments in a DRP1-independent manner.  The fusion of a 
lysosome to the phagophore (a mitolysosome) results in the breakdown and recycling of 
mitochondrial molecules.  The remaining functional mitochondrial segments are fused 
together by the interaction of mitofusion 1 and 2 (Mfn1 and Mfn2) on their outer membranes, 
which in damaged segments are ubiquitinated by Parkin to prevent them from fusing back to 
undamaged ones71.  Mitophagy is known to occur under homeostatic conditions basally, but 
is considerably elevated during periods of cell stress, particularly under redox stress or 
starvation72.  The role of mitophagy pathways in addressing mtDNA damage is less 
understood.  DNA damage is traditionally thought to trigger apoptosis via p53 and the 
intrinsic pathway, though low levels of mtDNA damage and heteroplasmy in which MMP is 
impaired may instead trigger mitophagy as a quality control73. 
Mitochondrial DNA as Damage Associated Molecular Patterns (DAMPs) 
The release of mtDNA from the mitochondrial matrix into the cytosol or extracellular 
space is a clear indicator of cell damage74; consequently, mtDNA can be a DAMP under 
conditions of high stress.  Intracellularly, damaged mtDNA accumulates in autolysosomes 
where it can be degraded by DNAse II75.  Accumulation of damaged mtDNA triggers 
mitophagy, and in more severe cases, cellular apoptosis73.  The presence of mtDNA in 
cytosol is sufficient to activate the NLRP3 inflammasome and release proinflammatory 
mediators such as interleukin-1β76.  Damaged mtDNA can also trigger type-I-interferon-
regulated antiviral genes through the cyclic GMP-AMP synthase (cGAS) intracellular DNA 
sensor77.  Additionally, cytosolic mtDNA can bind to and activate Z-DNA Binding Protein 1 





Extracellularly, the release of cell-free mtDNA is highly pro-inflammatory.  Cell-free 
mtDNA can be released through exocytosis79 or simply expelled through a cell membrane 
made permeable by cellular damage80-81.  Exosomes containing mtDNA may circulate 
through the bloodstream, potentially triggering a systemic response to the DAMPs.  
Plasmacytoid dendritic cells (pDCs) react to the presence of extracellular mtDNA as a viral 
infection and follow a chemokine ligand-2 (CCL2) gradient to the site of release82.  
Neutrophils are also activated and recruited, as extracellular mtDNA binds to Toll-like 
receptor 9 (TLR9) and promotes p38 MAP kinase signaling in these cells83. 
Mitochondria therefore have an important role in communication between epithelial 
cells and the innate and adaptive immune systems.  Redox stress sufficient to cause mtDNA 
damage in the epithelium generates circulating mtDNA DAMPs which can induce or 
exacerbate inflammation, even in the absence of cytotoxicity/apoptosis74.   
Mitochondria in the Human Airway 
Of all the organ systems in the human body, the lungs are among the most susceptible 
to exogenous insult.  Despite their relatively small size and weight (approximately 1.3kg for 
an adult), the average human lung presents an estimated 130m2 of surface area with which to 
conduct gas exchange with the ambient environment84.  More than any other organ in the 
body, oxidative stress is a daily occurrence, and because ambient air is not sterile, resident 
macrophages and near-constant inflammatory signaling from both the adaptive and innate 
immune responses are active within the airways to protect from infection by inhaled 
pathogens.  The mucociliary escalator, a protective layer of mucins and surfactant proteins 




entraps and removes inhaled particles to the epiglottis where they are swallowed.  
Chemically reactive particulates, such as diesel exhaust or wood smoke, can create a caustic 
milieu of peroxides and radicals within the mucus before they are cleared through ciliary 
action, and airway epithelial cells become the first targets of these chemicals.  Club cells, 
airway epithelial cells that specialize in secretion of surfactants and metabolic enzymes, 
contain cytochrome P540s that can metabolize many of these harmful inhaled toxins, though 
in some cases these metabolic reactions exacerbate toxic effects by generating genotoxic 
agents (such as in the case of metabolism of benzo[a]pyrene by CYP1A1)85.  The combined 
effect of all this exogenous and endogenous insult is a perpetual microenvironment of redox 
stress directly adjacent to bronchial epithelial cells, which rely on energy production by 
mitochondria to perform ciliary beating and replication of damaged cells.  This makes the 
human lung an ideal organ in which to study the relationship between somatic mitochondrial 
heteroplasmy and human disease. 
There are substantial differences between nuclear and mitochondrial DNA that make 
mtDNA more susceptible to environmental insult.  The most obvious of these differences is 
their relative positions within the cell.  Nuclear DNA is located centrally and is surrounded 
by a protective nuclear envelope.  This envelope consists of an inner lipid bilayer reinforced 
by a ~15 nm-thick nuclear lamina of cytoskeletal fiber and an outer lipid bilayer which is 
embedded with nucleoporins through which particles larger than 60 kDa require GTP-
dependent transport86.  By contrast, the mitochondrial DNA is located peripherally in the 
cytoplasm, and is protected only by an inner lipid bilayer membrane 6-8 nm thick (the outer 
membrane contains porins which make it highly permeable)87.  Another difference is in the 




wound into nucleosomes consisting of an octamer of histones, and nucleosomes are 
themselves coiled further into chromosomes88.  Consequently, nuclear DNA (in the inactive 
state) presents very little surface area for chemical interaction during environmental stress, 
because the 2-meter-long genome is coiled into a nucleus less than 10 μm in diameter89.  No 
such protective packaging exists for mitochondrial DNA, and the mtDNA forms circular 
plasmids which are fully exposed to the mitochondrial matrix at all times (while supercoiling 
of these plasmids does occur, it is not considered protective and the loss of supercoiling is a 
biomarker of mtDNA damage90).  Finally, mtDNA occupies a location that generates a high 
level of redox stress.  While compensatory mechanisms (such as superoxide dismutase 
SOD2) exist within the mitochondrial matrix, exogenous nucleophiles can oversaturate these 
mechanisms more easily than in the nucleus where there is no radical production, and SOD2 
can be converted into a pro-oxidizing peroxidase in the presence of iron91.  The combination 
of these factors ensures that when a cell is exposed to potentially genotoxic agents, mtDNA 
is more vulnerable than nucDNA, and this is also true for inflammatory lung diseases. 
Mitochondrial DNA Heteroplasmy as a Marker for Lung Disease 
Because of the highly vulnerable status of mtDNA, heteroplasmy is a potentially 
useful marker for lung disease.  Because mtDNA damage is known to occur prior to 
cytotoxicity78, it can be an early warning signal for various conditions that are initiated or 








Hyperoxia is a common treatment for acute respiratory distress, particularly in 
premature infants.  While the higher oxygen supplementation enables life-saving oxygen 
exchange, it also may result in acute lung injury from redox stress92.  This can cause an 
increase in membrane permeability in the alveolar epithelial cells, leading to fluid 
accumulation in the alveoli and impaired lung function.  Genotoxicity in hyperoxia has been 
well-documented93-95, therefore, mitogenomic effects are also likely.  Studies have found a 
reduction in mitochondrial function with prolonged exposure to hyperoxic conditions92, 96, 
with deletion of mitochondrial A-kinase anchoring protein (AKAP1) increasing the severity 
of these effects97.  Mitochondrial fragmentation (via Drp-1) can be triggered by hyperoxia, 
and mitigated by mitochondrial DNA repair92 with the in vitro addition of an ENDOIII 
enzyme promoting pyrimidine repair in pulmonary endothelial cultures.  Hyperoxia-induced 
mtDNA damage was also found in cardiomyocytes in vivo, indicating that the genotoxic 
effects of a high-O2 exposure can extend beyond the lungs98. 
Inhaled Pollutants 
Exposure to exogenous airborne pollutants is ubiquitous in developed nations (and 
common in developing nations through wood and biomass smoke), and many of these agents 
are known to be genotoxic.  Vehicle exhaust particles99, ozone100, volatile organic 
compounds (and their reactive products)101, coal fly ash102, many types of inhaled 
nanomaterials103-105, and asbestos106 cause DNA damage in the lung, though specific damage 
to mtDNA, particularly at lower doses, has not been as thoroughly investigated.  Recent 




does not necessarily predict mtDNA damage18, 107-108, which suggests that other factors are 
present, such as mtDNA repair/other compensatory mechanisms, site-specific activity, and/or 
dose-dependent differences.  This would likewise suggest that some pollutant exposures that 
are not considered genotoxic for nuclear DNA might damage mtDNA “under the radar” and 
have yet to be discovered. 
Early investigations into the link between mtDNA and ambient particle exposures 
focused on mtDNA copy number, generally in blood109-111.  Effects on mtDNA copy 
numbers were, however, often contradictory.  Increases112 and decreases113 in mtDNA 
abundance were both correlated with increasing exposures to inhaled particle matter.  Blood 
mitochondrial DNA copy number appears to have no discernable connection to 
mitochondrial function or particle exposure, making it a highly unreliable marker.  Therefore, 
there is a current need for additional research on other mitogenomic endpoints, such as 
heteroplasmy and epigenetic changes, which could provide a better mechanistic picture of the 
role of mtDNA in pollutant exposures.  In Chapter 2, I demonstrate that in vitro exposure of 
primary bronchial epithelia to multi-walled carbon nanotubes cause no changes in mtDNA 
sequence or heteroplasmy at any non-cytotoxic dosage, despite observed effects on oxygen 
consumption, mitochondrial mass-per-cell, and upregulated mtDNA gene expression18.  
These effects were not observed with other nanomaterials (nanographite, nanosilver, and 
nanoceria), the results of which I have included in Appendix 2.  Transmission electron 
microscopy (TEM) images show penetration and depolarization of mitochondria by the 
nanotubes, suggesting that the effects of these particles were physical rather than genotoxic.  




suggesting that the loss of mitochondrial abundance and upregulated gene expression may be 
due to mitophagy and compensatory biogenesis. 
Smoking 
In addition to a source of inhaled particulate matter, tobacco smoke contains a 
multitude of carcinogenic and mutagenic compounds.  The vulnerability of mtDNA to 
tobacco smoke has been explored in the lungs of smokers and in newborns following in utero 
exposure114.  Acrolein is a known genotoxic component of tobacco smoke that forms adducts 
to mtDNA, leading to translesion synthesis by Polγ and mtDNA mutations.  Mitochondrial 
morphology, metabolic function, and mtDNA copy number are also altered by exposure to 
tobacco smoke115.  Cell-free mtDNA, an inflammatory DAMP, is greatly elevated in the 
saliva of smokers116. 
Chronic obstructive pulmonary disease (COPD), particularly emphysema, is a well-
established consequence of prolonged exposure to tobacco smoke117.  COPD is driven, in 
part, by cellular senescence triggered by tobacco smoke118, and therefore mitochondrial 
dysfunction is likely to have an important role in its pathogenesis.  Ahmad et al119 found that 
mitophagy was impaired in human lung fibroblasts and small airway epithelial cells exposed 
to cigarette smoke.  The authors found that elevated p53 (induced by the cigarette smoke) 
reduced translocation of Parkin to depolarized mitochondria and prevented mitophagy.  A 
study by Zheng et al120 of 671 COPD and 724 non-COPD patients from southwestern China 
found an association with specific haplogroups of mtDNA (namely A and M7) associated 
with increased susceptibility to COPD, as well as other haplogroups (D, F, and M9) which 




be influenced by mtDNA sequence suggests that oxidative stress and mtDNA damage from 
smoking may preferentially target base sequences found in some haplotypes and not others.  
Impaired mitophagy would compound this issue by preventing turnover of damaged 
mitochondria.  A more complete picture of the role of mitogenomics in COPD and smoking 
requires additional research into these targeted sequences and the overall effect mtDNA 
damage would have on lung function. 
Asthma 
Asthma is one of the most widespread chronic inflammatory lung diseases in 
developed countries and remains among the most common causes of childhood admission to 
hospitals in the US.  Asthma can be further divided into the broad subgroups (endotypes) of 
eosinophilic/allergic asthma, which is more widespread, and neutrophilic asthma, which is 
generally more severe and less responsive to inhaled corticosteroids121.  Both are 
characterized by chronic/repeated inflammation of the airways, recruitment of leukocytes, 
epithelial redox stress, and cellular damage.  It therefore follows that asthma might also cause 
adverse effects on the mitochondrial genome.  Work by Sebag et al122 demonstrated that 
inhibition of Ca2+/calmodulin-dependent protein kinase II (CaMKII) in the mitochondrion 
reduces mitochondrial oxidative stress and reduces inflammation in allergic asthma models, 
which suggests that mitochondrial ROS has a specific and important role in the pathogenesis 
of asthma. 
While the relationship between asthma and oxidative stress is well known (though 
incompletely understood), the effects of asthma on the mitochondrial genome is only 




the induced sputum of human patients with asthma and/or COPD compared to healthy 
individuals.  The authors considered mtDNA/nucDNA ratio to be a potential biomarker for 
asthma.  In Chapter 3, I found downregulated expression of mitochondrial genes and 
increased mtDNA heteroplasmy and unprocessed mitochondrial RNA transcripts in bronchial 
epithelial cells (BECs) of patients with fatal asthma compared to healthy controls.  Because 
these effects were found in BECs after multiple passages following extraction from the lungs, 
it suggests that the conditions within severely asthmatic lungs induce lasting impairment of 
the mitochondrial genome of BECs in the conducting airways.  However, ultradeep 
sequencing of these mtDNAs revealed no significant changes in insertion/deletion mutations.  
Further research into the mechanisms of mitochondrial dysfunction in asthma are currently 
needed to determine whether there are epigenomic effects or changes in nuclear regulation 
which might explain these effects. 
Cystic Fibrosis 
Cystic fibrosis (CF) is a genetic condition arising from a dysfunctional cystic fibrosis 
transmembrane conductance regulator (CFTR) gene124.  This protein normally transports Cl- 
ions from the cell into the extracellular space, allowing water to diffuse into the extracellular 
liquid and decreasing its viscosity.  When this transport is impaired, particularly in the 
epithelium of the lung and pancreas, extracellular mucus becomes highly viscous and 
immobile, and may occlude airways/ducts and entrap pathogens and inflammatory 
cells/mediators in the mucus.  This causes chronic inflammation and remodeling/widening of 
the airways (bronchiectasis) to allow lung function, eventually leading to death by 
progressive lung failure.  Several mutations can lead to dysfunctional CFTR, and the most 




homozygous ∆F508 mutation is by far the most common cause of the cystic fibrosis 
condition. 
Mitochondrial genomics in cystic fibrosis is poorly understood.  Oxidative stress in 
the mitochondria of CFTR-deficient cells has been reported126.  CFTR has a role in the 
transport of glutathione (GSH) to the extracellular space and therefore dysfunctional CFTR 
can exacerbate the oxidative stress of CF patients.  Velsor et al127 found decreases in 
mitochondrial GSH of 85% and 43%, respectively in CFTR knockout mice and CFTR-
deficient human lung epithelial cells.  Flow cytometry confirmed increased cellular ROS in 
CFTR-deficient cells, and increased 8-hydroxy-2-deoxyguanonsine (8OHdG) lesions were 
found in the mtDNA of these cells, supporting the hypothesis that CFTR deficiency can lead 
to mitogenomic damage even in the absence of pathogens or inflammatory mediators.  My 
work in Chapter 3, utilizing ultradeep sequencing and extracellular flux assays of primary 
bronchial epithelial cells isolated from the lungs of CF patients, is consistent with this effect.  
Heteroplasmy in CF cells was increased compared to healthy, non-CFTR deficient cells and 
uncoupled oxygen consumption was significantly decreased.  This further suggests that the 
epithelial oxidative stress caused by CF results in persistent mtDNA mutations and impaired 
mitochondrial function.  While these results suggest a consistent and convincing presence of 
mitogenomic damage in the CF lung, studies that investigated this phenomenon are relatively 
few, and additional clinical work including larger numbers of CF patients is currently 
needed.   
The treatment of CF underscores another important interaction with mtDNA.  Control 
of airway infections during CF often requires treatment with aminoglycosides, such as 




1555A>G transition128.  This has resulted in a push towards mtDNA screening for CF 
patients prior to treatment129.  
Summary 
 The mitochondrial genome of human BECs is a particularly vulnerable, yet vital and 
understudied, piece of the puzzle of oxidative lung injury.  In the following chapters, I will 
be testing the hypothesis that conditions which result in oxidative lung injury can damage the 
mtDNA of human BECs, resulting in heteroplasmy and subsequent impairment in 
mitochondrial gene expression and cellular metabolism.  In Chapter 2, I focus on the 
mitogenomic effects in BECs resulting from acute (5 day) exposures to nanomaterials, 
including carbon nanotubes, nano-graphite, nano-silver, and nano-ceria.  Then, in Chapter 3, 
my research examines BECs from human donors with chronic inflammatory lung diseases, to 
determine whether these conditions can generate epithelial mitogenomic impairment which 















Figure 1.1 Overview of mtDNA during oxidative lung injury. This schematic represents the 











Figure 1.2 Illustration depicting 3 types of mitochondrial heteroplasmy.  Homoplasmy (left), 
which is the absence of a minor allele, microheteroplasmy (right), which is the 
homeostatically-maintained presence of low-frequency minor alleles (generally less than 2-
10%), and heteroplasmy (bottom), which is the presence of a biologically-significant 










Figure 1.3 Mitochondrial responses to oxidative lung injury and cellular stress.  The 
mitochondrion is a “canary in the coal mine” for exogenous and endogenous stress, and there 
are many measurable endpoints that can be assessed to quantify the effects of mitogenomic 







CHAPTER 2: MULTI-WALLED CARBON NANOTUBES UPREGULATE 
MITOCHONDRIAL GENE EXPRESSION AND TRIGGER MITOCHONDRIAL 
DYSFUNCTION IN PRIMARY HUMAN BRONCHIAL EPITHELIAL CELLS1 
 
Introduction 
Over the last 20 years, nanomaterials have emerged as one of the most promising 
advances in material science.  The unique properties particles acquire at the nano-scale 
(having at least 1 dimension less than 100 nm) have resulted in an explosion of new 
applications and products, including construction materials130, medical advances131-132, 
industrial applications133-134, hydrophobic or absorbent textiles135, superblack or reflective 
surfaces136, and many others137-139.  Carbon nanotubes are already ubiquitous in consumer 
products, second only to antimicrobial nanosilver in its prevalence140.  Multi-walled carbon 
nanotubes (MWCNTs), which consist of multiple layers of graphene rolled into a tube, 
possess the highest tensile-strength of any other man-made material141, as well as 
semiconductivity and hydrophobicity142-143, properties which have made them valuable for 
use in concrete reinforcement, sporting goods, space travel, electronics/sensors, stain-free 
fabrics, and even cancer treatments144-145.  Consequently, the public’s exposure to MWCNTs 
and risks of inhalation, both by consumers and as an occupational hazard, are of great 
concern. 
Despite the incorporation of these materials into the public domain, early studies into 
the health risks associated with exposure to carbon nanotubes have discovered toxic effects 
                                                 
1 This chapter previously appeared as an article in Nanotoxicology.  The original citation is as follows: Snyder 
RJ, Verhein KC, Vellers HL, Burkholder AB, Garantziotis S, Kleeberger SR “Multi-walled carbon nanotubes 
upregulate mitochondrial gene expression and trigger mitochondrial dysfunction in primary human bronchial 




including oxidative stress146-147, cytotoxicity/apoptosis148-150, genotoxicity151-152, and impaired 
cellular function and differentiation153-155.  Clearance of nanotubes following inhalation 
exposure is typically very slow, persisting in the lungs for several months afterwards156.  As a 
fibrous material with a high aspect ratio, carbon nanotubes can cause frustrated 
phagocytosis149 by resident macrophages, which can lead to chronic inflammation157-158, 
granulomas159, and pulmonary fibrosis146, 160.  Nanoparticles are small enough to penetrate 
the cell membrane161-162, and can enter the cytosol either passively162-163 or following 
phagocytosis164-165 by the cell.  The ability of carbon nanotubes to passively penetrate the 
plasma membrane, though potentially therapeutically useful as a drug-delivery vehicle163, 166, 
may also elevate the threat these particles pose to intracellular organelles, particularly at 
shorter (<200nm) fiber lengths167.  Genotoxicity from nanotube exposure has also been 
described151-152, indicating that carbon nanotubes are capable of damaging DNA within the 
nucleus following uptake by the cell. 
In this chapter, I hypothesized that MWCNTs can also exert genotoxic effects on 
mitochondrial (mt)DNA, which is less protected than nuclear DNA168-169, thereby impairing 
mitochondrial function in exposed cells.  To test this hypothesis, primary bronchial epithelial 
cells were obtained from healthy human volunteers via bronchoscopy and grown to 
confluence for five (5) days in submerged culture containing non-cytotoxic doses of 
MWCNTs.  Cellular DNA and RNA were harvested for mitogenomic endpoints including 
changes in mtDNA heteroplasmy, insertion/deletion (indel) mutations, and expression of 
mitochondrially-encoded genes by QPCR.  Exposed cells were also assessed for oxygen 
consumption rate using the Seahorse XF extracellular flux assay, as well as verification of 
cytotoxicity by lactate dehydrogenase (LDH) release and ultrastructural imaging of 






Materials and Methods 
Nanomaterial Characterization 
The MWCNTs we used were sourced from Helix Nanomaterial Solutions, and were 
characterized by an independent laboratory (Millennium Research Laboratories, Woburn, 
MA), in a previous publication170 to be >95% purity as measured by thermogravimetric 
analysis (TGA) with <2% amorphous carbon.  Inductively-coupled plasma Auger electron 
spectroscopy (ICP-AES) performed by MRL determined the bulk sample to consist of 99% 
carbon, 0.63% oxygen, 0.34% nickel, and 0.03% lanthanum.  Particle agglomeration in the 
dispersion medium used in these studies was measured and reported previously154 using 
dynamic light scattering (DLS) analysis.  Agglomerates have a Z-average of ~200 nm in 
hydrodynamic diameter, with most of the mass of the agglomerates forming between 10-100 
nm. Individual fibers were present and abundant in TEM imaging during this study, and were 
usually found between 30-50 nm in diameter, and 100-1000 nm in fiber length.  
Qualitatively, fiber morphology varied in apparent stiffness, with agglomerates of longer 
fibers being tangled/bent and individual or shorter fibers appearing more rigid. 
Cell Culture and Treatment 
Bronchial epithelial primary cells (BECs) were obtained from bronchoscopy 
brushings of 8 “healthy” (non-smokers without current lung disease) human donors, aged 23-
32 years (donor demographics can be found in Table 2.1).  Bronchoscopy of human donors 
and the use of cells derived from this procedure was performed after review and approval by 
the National Institute of Environmental Health Sciences Intramural Review Board (NIEHS-
IRB, clinicaltrials.gov identifier: NCT01224691).  Bronchoscopies were performed with the 
donors’ written consent by a trained pulmonologist (S. Garantziotis) at the NIEHS Clinical 
Research Unit (CRU) per the methods described in NIH protocol 11-E-0006.  Following a 




surface mucosal epithelial cells.  After each brushing, the brush was removed and the 
recovered cells were dislodged from the brush by stirring in a 15 mL conical vial containing 
Bronchial Epithelial Growth Medium (BEGM, Lonza) supplemented with 2x amphotericin 
B.  Cells from brushes were seeded onto T-25 vented flasks in serum-free Lonza BEGM 
medium and frozen at passage 1.  For each experiment, cells were thawed in BEGM for 
expansion in T-75 flasks, further subpassaged onto either 6-well or 96-well plates, and were 
exposed to nanomaterials at passage 3 while the cultures reached confluence.  Cultures 
received a media refresh every 2 days containing freshly-dispersed nanotubes, and were 
exposed again at days 1, 3, and 5 following seeding. 
 MWCNTs were dispersed in BEGM culture medium supplemented with sterile 600 
μg/ml bovine serum albumin (BSA) and 10 μg/ml 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) surfactant.  Pulmonary surfactant, while not secreted by bronchial 
epithelia in the adult lung, does protect non-ciliated BECs in vivo in the bronchioles near 
alveoli171, and its use is consistent with recommendations by the Nano GO Consortium for 
optimal dispersion of MWCNTs172.  Control vehicle (CoV) exposures used the supplemented 
medium without nanomaterials.  Prior to exposure, stock solutions of MWCNT (2 mg/ml) 
were sonicated in a cup horn for 15 minutes (5 pulses of 3 minutes each) at 100 amplitude to 
break up agglomerated materials, then diluted to treatment concentrations in dispersion 
vehicle at 0.7-12 μg/ml MWCNT.  Some sedimentation of the MWCNTs did occur between 
treatments upon visual examination, though precisely what percentage of the MWCNT mass 
sedimented could not be conclusively determined.  The 0.7, 3, and 12 μg/ml MWCNT doses 
would equate to approximately 0.25, 1, and 4 ug/cm2 if the nanomaterial sedimented out 
completely between treatments, and approximately 0.75, 3, and 12 ug/cm2 if the MWCNTs 
were completely absorbed by the cells before each wash, placing these as upper bounds on 




determined for these cells previously154, we also verified cytotoxicity for this experiment by 
lactate dehydrogenase (LDH) release assay and trypan blue exclusion. 
LDH Release Cytotoxicity Assay 
Supernatant from BECs exposed to nanomaterials or dispersion vehicle (24 hours 
following the most recent media refresh at 24 hours and 5 days) was centrifuged and 
transferred to a clear-bottom 96-well plate.  Acellular treated wells were also included to 
account for interference from the particles.  LDH accumulated over 24 hours was assessed 
using the CytoTox colormetric assay (Promega) and compared to dispersion vehicle controls 
to verify that the nanomaterial exposures used in this study were not causing significant 
cytotoxicity. 
Trypan Blue Exclusion Assay 
BECs treated with MWCNTs for 24 hours and for 5 days were assessed for 
membrane permeability by staining with trypan blue dye (Sigma Aldrich).  Cell cultures were 
washed 3x with phosphate buffered saline (PBS) and lifted into suspension using 0.25% 
trypsin-EDTA solution (Sigma Aldrich) at 37°C for 4 minutes.  The reaction was terminated 
with 2 mg/ml soybean trypsin-inhibitor (SBTI) and cell suspensions were pelleted in a 
centrifuge at 1000 rcf for 5 minutes, then resuspended in a 1:1 solution of BEGM and trypan 
blue dye.  Counts of live and dead cells were performed manually using a hemocytometer at 
20x magnification. 
Quantitative PCR 
Following 5-day nanomaterial exposures in a 6-well plate, BECs were harvested for 
total RNA using the RNeasy columns/reagents and QiaCube automated isolation/purification 
device (Qiagen), according to manufacturer’s protocol.  Total RNA was converted to cDNA 
libraries using iScript reverse transcription kits (BioRad) containing oligo dT’s and 




2.2 for amplicon context sequences) for all 13 mitochondrially-encoded protein-coding 
genes, plus sequences for ubiquitin C (UBC), 18S, and 16S endogenous controls, were used 
for gene expression analysis of the cDNA libraries by quantitative PCR (QPCR).  SSO 
Advanced SYBR Green master mix was used as a reporter dye in a StepOne real-time 
sequencer (ABI Technologies).  Assays were measured over 40 cycles, denaturing at 95°C 
for 5 seconds and annealing at 60°C for 30 seconds. 
Amplification of mtDNA 
Total DNA was harvested from BECs exposed to nanomaterials for 5 days in 6-well 
plates using a cell scraper in 4°C phosphate buffered saline (PBS).  Cell suspensions were 
lysed with protease K and DNA extracted using DNeasy Blood and Tissue columns and 
QiaCube automated isolation/purification device (Qiagen).  Mitochondrial DNA (mtDNA) 
was amplified from these samples using the SequalPrep Long PCR kits with dNTPs and the 
following primer sequences, resulting in “short” (7626 bp) and “long” (9286 bp) mtDNA 
fragments173: 
Long Fragment: 
forward-AAC CAA ACC CCA AAG ACA CC  
reverse-GCC AAT AAT GAC GTG AAG TCC 
Short Fragment: 
forward-TCC CAC TCC TAA ACA CAT CC 
reverse-TTT ATG GGG TGA TGT GAG CC 
 Agarose (0.8%, SeaKemp) gel electrophoresis was used to verify the presence and 
size of mtDNA fragments (see Appendix 1).  Removal of nuclear DNA, dNTPs, 




columns (Zymo) according to manufacturer instructions to prepare the mtDNA for 
sequencing. 
Ultra-Deep Sequencing 
Purified mtDNA from MWCNT-exposed BECs were sequenced for the appearance of 
heteroplasmies and indel mutations compared to the sequences of vehicle-treated control 
cultures.  Tagmentation of mtDNA (combined short and long fragments) was carried out 
using a Nextera DNA Library Prep kit (Illumina) according to the manufacturer’s 
instructions.  DNA samples were added to a 96-well thermal cycler plate with Amplicon 
Tagment Mix and Tagment DNA buffer from the kit and heated at 55°C for 5 minutes.  
Libraries were then amplified with indexed adapters and Nextera PCR Master Mix, first 
denaturing at 72°C and then running 15 cycles of 95°C for 10 seconds, 55°C for 30 seconds, 
and 72°C for 30 seconds.  AMPure XP magnetic beads (Illumina) were used to purify the 
resulting mtDNA libraries, according to manufacturer instructions.  AMPure beads were 
added to each sample and allowed to incubate at room temperature for 7 minutes on a 
magnetic plate to pellet the DNA/beads.  Supernatants were discarded and the bead pellets 
were washed twice with 80% ethanol, then allowed to air dry completely (approximately 10 
minutes).  Purified DNA was resuspended in AMPure Resuspension Buffer and the DNA 
concentration/quality was verified by QuBit High-Sensitivity Analysis (Thermo-Fisher) and 
the Agilent Bioanalyzer. 
Alignment and Variant Calling 
Read pairs were aligned using bowtie2, version 2.0.0-beta7, to an index composed of 
the human mitochondrial genome only, acquired from GenBank May 2015 (accession 
NC_012920).  The alignments were performed in “--local” mode using the “--sensitive-local” 
preset options to allow insertions and deletions relative to the reference, as well as clipping of 




lengths of up to 10kb were allowed, as well as a single mismatch per seed alignment (-X 
10000, -N 1). 
 Variants were identified with a custom script, utilizing a method adapted from 
Hodgkinson, et al.174.  For each sample, depth per allele, per strand was determined, allowing 
a minimum base and alignment quality score of 20.  Indels relative to the reference were 
counted only in the case that both flanking bases’, and any inserted bases’ quality scores met 
or exceeded this threshold.  Additionally, the depth calculation for sites adjacent to or within 
homopolymer runs considered only reads traversing the entire repeat.  Sites with less than 
2000x coverage were not considered, and variants were required to be observed at a 
frequency of 1% or greater, with a plus to minus strand coverage ratio greater than 0.1 and 
less than 0.9.  The probability of observing each alternate allele by chance was calculated 
using a Poisson distribution, with an expected error rate of 0.01 for SNPs (derived from the 
quality score threshold), and 0.02 for indels, based on observations reported by Minoche, et 
al175.  These p-values were adjusted for multiple testing using the Benjamini and Hochberg 
FDR method, and a significance threshold of 0.05 was applied.   
Extracellular Flux Assay (Seahorse XF) 
An extracellular flux assay was used to determine changes in oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) in BECs exposed to nanomaterials.  
Primary BECs were seeded onto a 96-well Seahorse XF96 microplate in BEGM.  Cells were 
allowed to reach confluence, with fresh changes of medium containing MWCNTs or vehicle 
every 2 days, as described above (Cell Culture and Treatment).  On the day of the assay, 
cells were washed 3 times with PBS and fed 180 μl/well of pre-warmed (37°C) Seahorse XF 
medium, consisting of XF Base medium with additional supplements of 1mM sodium 
pyruvate, 11 mM D-glucose, and 2 mM L-glutamine, with the pH adjusted to 7.4 using 
NaOH and HCl.  The sensor cartridge (following an overnight incubation in XF calibrant 




Stress Test: 2 uM oligomycin (20 ul of 20 uM per well), 2uM Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP, at 22 ul of 20 uM per well), and 0.5 uM 
rotenone/antimycin A (25 ul of 5 uM per well).  The Seahorse XFe96 extracellular flux 
instrument was programmed to take 3 measurements before and after the injection of each of 
the 3 compounds, with each measurement having taken approximately 8.7 seconds.  All 
reagents used for Seahorse XF analysis were obtained from Agilent. 
MitoTracker and Annexin V Staining  
Live BECs from 4 “responding” donors (donors which exhibited a gene expression 
response to the MWCNTs) were treated with MWCNTs at 0, 0.7, and 3 μg/ml for 5 days, 
washed with BEGM, then incubated in 6-well culture plates with 100uM MitoTracker Deep 
Red FM dye (Thermo Fisher) for 45 minutes at 37°C.  Wells were then washed with BEGM, 
passaged into 2 ml microcentrifuge tubes (using 0.25% trypsin/EDTA and 2 mg/ml SBTI), 
and resuspended in 1x calcium binding buffer for annexin V staining (TACS Apoptosis 
Detection kit, Trevigen).  Cells were incubated in suspension with 15 ul of propidium iodide 
and 1ul of FITC-conjugated annexin V per 100 ul of binding buffer for 15 minutes at room 
temperature.  Cells were then resuspended in 500 ul of ice-cold binding buffer for flow 
cytometry.  Flow cytometry was performed using a BD LSRFortessa instrument, with 10,000 
events counted per sample.   
Succinate Dehydrogenase Immunostaining   
In addition to MitoTracker, mitochondrial abundance per cell was also determined by 
immunostaining fixed cells for succinate dehydrogenase A (SDHA), a nuclear-encoded 
subunit of mitochondrial complex II.  BECs from 4 donors were exposed to MWCNTs 0.7, 3, 
and 12 μg/ml for 5 days, lifted from the 6-well plate with trypsin, fixed with 4% 
paraformaldehyde, washed 3x with PBS, then resuspended in 1:1000 anti-SDHA FITC-




flow cytometer was used to quantify FITC-labeled cells, with 2000 events counted per 
sample. 
Transmission Electron Microscopy (TEM) 
For ultrastructural imaging of nanomaterials within the cell, BECs exposed to 
nanomaterials for 24 hours were washed with PBS, removed from the 6-well plate with cell 
lifters, centrifuged at 800 rcf, and resuspended in fixative (4 parts formaldehyde and 1 part 
glutaraldehyde).  Cells were then re-pelleted at 1000 rcf and embedded in 3% water agar. 
Embedded samples were then processed using a Leica EM TP processor.  Samples were 
post-fixed in 1% osmium tetroxide, rinsed in water, then dehydrated in an ethanol series 
culminating in acetone.  Following dehydration, samples were infiltrated with Poly/Bed 812 
epoxide resin.  Blocks were trimmed and semi-thin (~ 0.5 µm) sections were cut, mounted on 
glass slides, and stained with 1% toluidine blue O in 1% sodium borate to visualize areas of 
interest via light microscopy.  Ultra-thin sections (80-90 nm thick) were cut from selected 
blocks and placed onto 200 mesh copper grids.  Digital images were captured with a Gatan 
Orius SC1000/SC600 attached to a FEICO Tecnai T12 transmission electron microscope.  
Confocal Imaging of Mitophagy 
BECs from responding donors (BECs 2, 4, 6, and 8) were treated with 3 μg/ml 
MWCNTs for 2 hours to observe their early mitophagy response.  Confluent cultures in 4-
well glass chamber slides were pre-treated with “Mtphagy” Mitophagy Detection Dye 
(Dojindo Molecular Technologies, Inc., Washington, DC) at 1/1000 dilution in BEGM for 30 
minutes at 37°C.  This dye locates to live mitochondria in vitro and becomes fluorescent on 
exposure to low pH, indicating interaction with lysosomes during mitophagy.  Vehicle 
medium containing 3 μg/ml MWCNTs was applied to BECs following 3x wash with PBS.  
FCCP was used at 5 μM as a positive control for mitophagy.  Mitochondrial division 




mitophagy, and was used to verify that MWCNTs were triggering mitophagy in the cells and 
not interacting with the dye or otherwise confounding the assay.  In these wells, 100 μM 
Mdivi-1 was added to MWCNT-containing treatment medium.  Following a 2-hour nanotube 
treatment, wells were again washed 3x with PBS and counterstained with the lysosome dye 
included in the kit, at 1/1000 dilution in BEGM, for 30 minutes.  Following a final wash step, 
the cultures were mounted with coverslips using Prolong Gold antifade reagent (Thermo 
Fisher) and imaged using a Zeiss 780 confocal microscope.  Z-stacks of 10 μm of cell 
monolayer were collapsed into a summation image, with a threshold intensity of 40 applied 
to generate a binary image of dye distribution.  Pixel density analysis was performed using 
Image J software and the ratio of mitophagic vesicles to lysosomes was calculated for each 
image.  Parameters such as gain, pinhole, laser intensity, z-planes per stack, and image post-
processing were kept consistent between treatments. 
Statistics  
Unless noted otherwise, the statistical significance of differences found between 
treatments was determined by one-way analysis of variance (ANOVA) on the means 
averaged from all the donors tested, with Tukey’s post hoc test for multiple comparison 
correction.  An adjusted p-value of 0.05 or less was considered statistically significant. 
Analysis of mitochondrial gene expression was performed using a 2-way ANOVA for each 
treatment, making comparisons between donor reactions to nanomaterials for each of the 13 





Nanomaterial doses were non-cytotoxic 
No statistically significant difference in trypan blue exclusion or extracellular LDH 
(Figure 2.1) was found at MWCNT doses of 3 μg/ml or less compared to vehicle-treated 
controls.  Results were similar for a 24-hour exposure and a 5-day repeated exposure, though 
12 μg/ml MWCNT doses were found to be cytotoxic by day 5.  The 3 μg/ml treatments we 
used were therefore determined to be non-cytotoxic over the time course and conditions used 
in this study, and the observed cellular and metabolic effects of MWCNTs at this dose were 
therefore not a consequence of cell death. 
Likewise, annexin/PI staining of 5-day treated BECs revealed no significant increase 
in apoptosis or necrotic cell death in MWCNT doses up to 3 μg/ml (Figure 2.2).  This 
provides further evidence that the mitochondrial effects observed in this study occur 
independently of apoptosis and do not result in apoptosis within the 5-day time course of this 
study. 
MWCNT exposure upregulated mitochondrial gene expression 
Expression of all mitochondrially-encoded genes was measured by QPCR (Figure 
2.3).  Cycles to reach threshold (Ct) values were normalized to expression of 18S ribosomal 
RNA using ddCt analysis.  BEC responses to 3 μg/ml MWCNT exposure varied between 
donors, with upregulated expression of mitochondrially-encoded genes in some donors 
(BECs 2, 4, 6, and 8) by up to 2-3-fold vehicle-treated values (with a combined average of 
1.4-fold overall upregulation, p<0.0001, 2-way ANOVA, Tukey comparison correction).  
These donors were considered “responders” and metabolic function assays performed later 
focused on these 4 donors.  Expression of these genes in donor BECs 1, 3, 5, and 7 treated 




No effect on heteroplasmy or mitochondrial mutations 
The mitochondrial genomes of BECs treated with 0.7-12 μg/ml MWCNTs were 
sequenced and examined for heteroplasmy/SNP variants and insertion/deletion mutations 
(Figure 2.4) compared to the hg19 human reference sequence, both at 24 hours following 
their first treatment and after 5 days.  Across all doses, we found no differences in major 
sequence variants compared to respective control groups.  We found an average of 
approximately 3 ± 1 indels (with sizes ranging from 1-3 base pairs) in mtDNA compared to 
hg19 (N = 8), and no treatment was statistically different from vehicle treatments.  
Heteroplasmy of single-nucleotide polymorphisms (SNPs) in which 10% or more of the 
mtDNA sequences contained the SNP compared to hg19 were averaged among the 8 donor 
BECs.  Vehicle-treated control BECs (CoV) averaged 8.58 ± 2.18 heteroplasmies compared 
to the hg19 reference sequence, and nanomaterial treatment did not cause heteroplasmy 
counts that were statistically different from vehicle controls. 
MWCNTs decreased intracellular mitochondrial abundance 
Mitochondrial abundance per cell was determined by flow cytometry, using 1) a 
FITC-labeled primary antibody against succinate dehydrogenase (SDHA), a nuclear-encoded 
mitochondrial membrane protein, and 2) in a separate experiment, MitoTracker Deep Red 
FM dye in live cells.  Fluorescent intensity of FITC staining per cell/event was averaged for 
4 donors (the highest gene expression responders, BEC2, 4, 6, and 8) and compared between 
vehicle controls and 3 doses of MWCNTs (0.7, 3, and 12 μg/ml) to determine whether the 
changes in mitochondrial gene expression observed with MWCNT exposure correlated with 
a change in mitochondrial abundance (Figure 2.5).  A statistically significant decrease in 
SDHA staining was found with increasing doses of MWCNTs (N = 4, paired t-test, p < 0.05).  
A similar pattern was found with MitoTracker (Figure 2.6), and a significant and dose-
dependent decrease in MitoTracker staining intensity per cell was found compared to 




Decreased oxygen consumption rate 
Oxygen consumption rate (OCR) before and after addition of oligomycin, FCCP 
uncoupler, and rotenone/antimycin was measured in a real-time extracellular flux assay in a 
96-well plate.  OCR values were then normalized to the total protein content in each well, 
determined by BCA assay, and averaged over 6 duplicate wells (Figure 2.7) of cells from 
responder BECs 2, 4, 6, and 8.  OCRs for MWCNT-treated cells were consistently and 
significantly reduced compared to vehicle-treated control cultures (p < 0.025) at baseline and 
following FCCP uncoupling.   
MWCNTs found in cytoplasm and intracellular organelles 
Transmission electron micrographs of BECs treated for 24 hours with 3 μg/ml 
MWCNTs enabled qualitative analysis of the intracellular distribution of these materials 
(Figure 2.8). MWCNT fibers were found outside of endosomes/phagolysosomes within the 
cytoplasm (Figure 8A), which suggested that these fibers were either capable of penetrating 
the plasma membrane (as seen in previous studies162-163) or were capable of escaping 
phagosomes following endocytosis by the cell164.  Particles were also found within double-
membrane bound structures that were suggestive of mitochondria. While these structures 
were too damaged for positive identification as mitochondria, the presence of individual 
MWCNT fibers within them provide non-quantitative evidence of MWCNT’s ability to 
penetrate intracellular membranes. 
Mitophagy response to MWCNT exposure 
BECs exposed to 3 μg/ml MWCNTs for 2 hours were assessed for mitophagy using 
confocal microscopy (Figure 2.9).  An uncoupling agent, FCCP, was used as a positive 
control of mitophagy.  Activation of the mitophagy dye by mitochondria/lysosome mergers 




controls (p < 0.001, N = 4, ANOVA, Tukey post-hoc).  This response was attenuated in 
BECs that were co-treated with Mdivi1, a drp1 and mitophagy inhibitor (p < 0.01). 
 
Discussion 
While genotoxicity resulting from exposure to nanomaterials has been previously 
documented151, specific effects on the mitochondrial genome, and function of mitochondrial 
organelles, have been relatively unexplored.  In this chapter, we tested whether carbon 
nanotubes, one of the most widely-used nanomaterials, could cause mitochondrial 
genotoxicity and impaired oxidative phosphorylation in human BECs.  BECs obtained from 
eight healthy human donors (via bronchoscopy) were exposed in submerged culture to 
MWCNTs or a dispersion vehicle control for five days, until they reached confluence.  We 
found that while MWCNT exposure did not induce significant mutations or heteroplasmy in 
primary BECs, they did cause significant upregulation of mitochondrial genes with inter-
individual variation between donors.  MWCNTs also decreased intracellular mitochondrial 
abundance and oxygen consumption, and induced mitophagy in exposed cells. 
 We used a primary bronchial epithelial cell model for these studies to better replicate 
the mitogenomic diversity found in the human population176 than would a cell line.  
Epithelial cells were an ideal model for this study as they would be expected to encounter the 
highest concentrations of inhaled nanomaterials in vivo and can be grown in medium without 
serum supplementation.  MWCNTs bind to serum proteins via hydrophobic interactions and 
could potentially affect concentrations of serum components in the medium177.  We used an 
exposure period of five days for this study to provide enough time for nanomaterials to cause 
detectable mitogenomic effects.  MWCNTs persist in the lungs of exposed mice for several 
months156, therefore, this exposure duration is realistic without being so long as to introduce 




this study were intentionally high (short of cytotoxicity) in comparison to a typical 
occupational exposure178.  One reason for this is because the purpose of this study was to 
determine whether MWCNT exposure could have effects on the expression and function of 
mitochondrial genes, and this question could best be answered initially with the highest 
dosage that would not cause necrosis or apoptosis.  The results we have reported with an 
MWCNT exposure of 3 μg/ml over five days indicate a modest effect on mitogenomic 
endpoints even in susceptible responder donors, while the more pronounced mitochondrial 
function and mitophagy findings suggest that mitochondrial injury might be present at lower 
doses.  Secondly, the use of bronchoscopy-derived BECs from volunteer donors inherently 
limited the scope of experiments which could be performed, due to the small numbers of P0 
cells (approximately 1-4 million) which could be obtained from each donor.  Consequently, 
performing this study with lower doses over longer timeframes was not possible.  Finally, 
comparing the dosimetry of inhaled MWCNT deposition into the human lung with that of a 
submerged BEC culture is inherently imprecise.  It would not be plausible to conclude that 
our in vitro nanotube exposure approximates a 6 month accumulated inhaled dose, for 
example, as the kinetics of mucociliary clearance, macrophage uptake, agglomeration in 
airway mucus, and many other factors would confound such an approximation.  Therefore, 
the doses and timepoints used in this study should be taken only as evidence that MWCNTs 
can cause mitochondrial dysfunction in human bronchial epithelial cells in isolation.  
Whether or not inhaled MWCNTs cause similar dysfunction in the lungs of those who 
interact with or manufacture these materials over a typical chronic exposure is beyond the 
scope of this study. 
 Carbon nanotubes are used in commercial applications in a variety of fiber lengths, 
structures, purities, added functional groups, and other variables, and so the choice of which 
nanotubes to use in this study was based primarily on whether they were found in products 




MWCNTs, such as the samples we sourced from Helix Material Solutions154, are commonly 
used in construction applications and textiles where a risk of inhalation exposure is present to 
consumers and manufacturers179.  While it is possible that greater or lesser mitogenomic 
effects could be obtained from testing nanotubes with other structural/chemical 
characteristics, the MWCNTs chosen for the current investigation are representative of the 
types affecting human health through inhalation exposure.  We also chose to use a dispersion 
medium supplemented with BSA during each MWCNT treatment.  This results in a protein 
corona around agglomerates in suspension which is known to increase active uptake of 
nanotubes in cell culture and reduce cytotoxicity180-181.  This method, which is recommended 
for optimum dispersion of MWCNTs in cell culture medium in accordance with the findings 
of the Nano GO consortium172, is justified for use in our exposure model as inhalation of 
MWCNTs would result in contact with extracellular mucus in vivo, therefore, it is highly 
likely that these nanoparticle aggregates would be surrounded in protein before encountering 
the epithelium.  MWCNTs absent a protein corona may conceivably have resulted in a lesser 
effect (from increased agglomeration leading to decreased cellular uptake) or greater effect 
(from a decreased proportion of MWCNT mass undergoing active transport leading to 
greater passive entry), but we believe the addition of the BSA to our dispersion vehicle more 
closely replicates in vivo exposure. 
 In Appendix 2, gene expression and ultradeep sequencing results for two other 
nanomaterial exposures, nano-silver (nAg) and nano-ceria (nCeO2) are shown.  As with 
MWCNTs, the highest non-cytotoxic dosage for each was applied to BECs for 5 days to 
measure their acute mitogenomic effects.  However, unlike MWCNTs, these nanomaterials 
did not significantly alter mitochondrial gene expression in most donor cells.  Oxygen 
consumption in BECs was unaffected by exposure to nAg or nCeO2, and since there were no 
mitogenomic or metabolic findings to report, these materials were not included in the later 




 Heteroplasmy, defined as the presence of intracellular variability in mitochondrial 
genome sequences, is only recently gaining recognition182-184 as a toxicological endpoint.  
Mitochondrial DNA sequences are usually well-conserved, even between species185, and so 
sequence variants resulting from exogenous insult/mutation often elicit functional detriments.  
As detection of heteroplasmy requires thousands of repeated sequencing reads at each 
position of the mitochondrial genome186, it is only due to the recent advancements in 
ultradeep DNA sequencing that a study measuring the effect of nanomaterials on shifting 
heteroplasmy of allele variants could be conducted.  Additionally, an increase in 
heteroplasmy, even at low levels, is linked to altered mitochondrial function187, a parameter 
which itself required recent advances in instrumentation (particularly the extracellular flux 
assay) to measure.  Following the 5-day exposure, heteroplasmy frequency was not changed 
(above 10% variant allele frequency) for any of the MWCNT doses used, compared to the 
same cells treated with dispersion vehicle (CoV).  Further, no change in the occurrence of 
indels was observed with MWCNT exposure.  The lack of changes in heteroplasmy and 
indels were unexpected findings, as genotoxicity in similar nanomaterials has been reported 
previously151-152, but these studies indicate that either cellular defense mechanisms protecting 
mtDNA from damage (primarily mitophagy) were more robust than anticipated, or that the 
nanomaterials were not used in doses/timeframes sufficient to induce such damage.  Longer-
term in vitro exposures would be possible through repeated treatments over multiple 
passages, though we have found donor-to-donor variability in the number of passages that 
primary BECs tolerate, and so the effect of chronic, low-dose MWCNTs on mtDNA may 
require use of a fully-differentiated air-liquid interface model or in vivo experiments.  The 
value of increasing the dosage to obtain genotoxic effects in mitochondria would be 
questionable, however, as the doses higher than those implemented in our study were 
cytotoxic and would be an improbable acute human exposure even in an occupational 
setting178.  Our results thus suggest that heteroplasmy and mutation in mtDNA are not 




However, MWCNTs did significantly affect mitochondrial gene transcription.  We 
found inter-individual variation in the responses between donors.  A 2-fold or higher 
upregulation of one or more mitochondrial genes was found in response to MWCNT 
exposure in four of the donors, and the remaining four donors were relatively non-
responsive.  With no demographic similarities or shared SNP/heteroplasmies to separate 
responders from non-responders, the source of this differential susceptibility is not currently 
known, though the variation may be due to differences in nuclear-encoded mitochondrial 
genes or increased susceptibility to redox stress or particulate matter in general.  The 
upregulation of mitochondrial genes in response to MWCNT exposure contradicted our 
original expectations that transcription would be impaired by induction of heteroplasmy.  We 
hypothesize that this upregulation indicates compensation by the cells to generate new 
mitochondrial subunits to replace those lost through mitophagy188-189 or direct damage from 
physical intrusion165 by the nanotubes.  This hypothesis would predict that MWCNT 
exposure depletes mitochondrial abundance per cell, which we measured by immunostaining 
for SDHA (a nuclear-encoded mitochondrial Complex II subunit) and MitoTracker dye in 
flow cytometry experiments.  We found a statistically-significant and dose-dependent 
decrease in mitochondrial abundance with MWCNT exposure.  We also used extracellular 
flux assay to measure the changes in metabolic function resulting from this loss of 
mitochondria and found that oxygen consumption rate (per unit of total protein), both basally 
and following uncoupling by FCCP, was significantly decreased by MWCNT exposure.  
These results suggest an overall impairment of mitochondrial abundance and function in 
human BECs by MWCNT exposure, despite the elevated transcription of mtDNA.   
Another outcome predicted by our hypothesis is that mitochondria damaged by 
MWCNT exposure would be recycled through mitophagy, thereby preventing the 
accumulation of damaged mtDNA and consistent with the absence of heteroplasmy.  We 




exposed BECs and found that mitophagy was highly induced after 2 hours of exposure.  This 
induction was attenuated by Mdivi-1, which inhibits mitophagy through drp1.  Mitophagy in 
MWCNT-exposed BECs was notably more pronounced than in the FCCP-treated positive 
controls.  This may be due to kinetic effects, wherein the chemical induction of mitophagy by 
FCCP peaks earlier and is more resolved by 2 hours, while the MWCNTs induce mitophagy 
later due to their having to penetrate the cells.  Electron micrographs following 5-day 
MWCNT treatments demonstrate the capability of the MWCNTs used in this study to enter 
the cytoplasm of exposed BECs, whether by escaping endosomes following active uptake164-
165 or by passively penetrating the plasma membrane162-163, though whether the physical 
presence of cytoplasmic MWCNTs is necessary for the induction of mitophagy is not yet 
known.  Future experiments to evaluate the kinetics of initiation and resolution of mitophagy 
in MWCNT-exposed BECs are planned, but the current results present a plausible 
mechanism that reconciles the upregulation of mtDNA genes with reduced mitochondrial 
abundance and function.   
 Our study has a few inherent limitations related to its translation to human toxicology.  
The study was performed in vitro to investigate whether, under the most ideal conditions, 
nanomaterial exposure could cause alterations in the mitochondrial genome.  While this 
eliminates many potential variables, factors that could attenuate or exacerbate any direct 
mitogenomic effects from the MWCNTs in an intact organism are beyond the scope of this 
study.  These factors include deposition190 of material in the lungs, other cells/tissues191 (e.g., 
resident macrophages), inflammatory responses16 to the nanomaterials, and co-exposures 
with other pollutants/chemicals/pathogens192.  Another inherent limitation is the use of a 
submerged epithelial culture model instead of an (arguably more physiologically-relevant193) 
air-liquid interface model.  This was done to eliminate donor-to-donor variation in 




comparison of mitochondrial genomics data with our extracellular flux data (an assay that, at 
present, cannot be performed using an air-liquid interface). 
 In summary, our findings suggest that mitochondrial turnover may be important for 
protection of the lung epithelium’s mtDNA from nanoparticle exposure.  Future studies are 
necessary to determine whether inhibition of mitophagy would result in increased 
mitogenomic effects from nanomaterials or whether the cell has other, undescribed 
mechanisms for protecting its mtDNA.  Additionally, the investigation of other forms of 
genotoxic stress for mitogenomic endpoints could result in new therapeutic measures for this 




Figure 2.1 Cytotoxicity in BECs at days 1 and 5 of MWCNT exposure, measured by trypan 
blue exclusion (A-B) and extracellular LDH (C-D).  Exposure to MWCNTs did not affect the 
percentage of cells permeable to trypan blue at any study dose by day 1 (A), but sharply 
increased cell death at the 12 μg/ml dose by day 5 (B).  Extracellular LDH was similarly 
unaffected by MWCNT treatments of 3 μg/ml or less, with a slight increase in LDH at day 1 
with 12 μg/ml MWCNTs (C) and a large increase at day 5 (D).  MWCNT doses of 3 μg/ml 
or less were determined to be non-cytotoxic for the purposes of this study. (N = 8, ANOVA, 










Figure 2.2 Apoptosis in MWCNT-exposed BECs was measured at day 5 by flow cytometry 
using annexin V-FITC staining with a propidium iodide counterstain.  MWCNT treatments 
of 3 μg/ml or less were not found to elevate annexin-positive cells or PI-permeable cells, 
indicating that apoptosis was not significantly induced by these treatments by day 5. (N = 4, 


















Figure 2.3 Mitochondrial gene expression in BECs exposed to 3 μg/ml MWCNTs, as 
measured by QPCR.  Values are expressed as fold control (dispersion vehicle-treated) BECs, 
with each symbol representing the mean of 3 experimental replicates of a different donor (A).  
Inter-individual variation was found across the mitochondrial genes in response to MWCNT 
exposure, while MTERF (a nuclear-encoded mitochondrial regulatory gene) transcription 
was not significantly altered by treatment.  Some donors were “responders” (such as BECs 2, 
4, 6, and 8, identified by p < 0.05 on 2-way ANOVA) that consistently upregulated all or 
most mitochondrial genes in response to MWCNTs, while others were not significantly 
changed from controls.  This donor variation is illustrated in (B), showing donor-specific 
patterns of up/downregulation when all genes from a given donor are combined.  Dotted lines 
indicate the standard deviation around the mean value for vehicle-treated controls (*p < 0.05, 































Figure 2.4 Frequency of heteroplasmy and insertion/deletion mutations (indels), as measured 
by ultra-deep sequencing.  Heteroplasmies with greater than 10% alternate allele frequency 
were counted (A) for each donor following treatment with dispersion vehicle (CoV) and 
MWCNTs at 0.7, 3, or 12 μg/ml.  Indels were also counted for each donor/treatment (B).  No 
statistically-significant differences were found between vehicle controls and any treatment, at 









Figure 2.5 Succinate Dehydrogenase A (SDHA) staining per cell, as measured by flow 
cytometry.  Average intensity of cellular FITC-labeled SDHA was used to determine 
mitochondrial abundance per cell, independent of metabolic activity.  Values are expressed 
as fold control FITC-staining intensity and show a dose-dependent decrease in mitochondrial 
abundance with increasing concentrations of MWCNTs from 0.7-12 μg/ml (MW07, MW3, 








Figure 2.6 MitoTracker staining per cell, as measured by flow cytometry.  Similar to SDHA 
immunostaining, the average fluorescent intensity of MitoTracker Deep Red FM dye taken 
up by the cell was used to measure mitochondrial abundance.  Results are expressed as mean 
raw intensity for each donor and show a dose-dependent decrease in intracellular 













Figure 2.7 Oxygen consumption rate (OCR) in donor primary BECs following overnight 
exposure to MWCNTs, measured by Seahorse Extracellular Flux assay.  OCR measurements 
at all time points were normalized to total well protein measured after the assay.  Baseline 
OCR was significantly reduced in MWCNT-treated cells compared to controls.  ATP-
coupled respiration measured following the addition of oligomycin was not significantly 
altered by MWCNT treatment, however, total reserve capacity of mitochondria uncoupled by 
FCCP was reduced.  No differences in non-mitochondrial respiration (following the addition 





















Figure 2.8 Sample images of transmission electron microscopy (TEM) of BECs treated with 
3 μg/ml MWCNTs for 24 hours.  A) MWCNT fiber found within the cytoplasm, unbound by 
any endosomal structure.  B) MWCNT fiber found within a double-membrane bound 






Figure 2.9 Confocal microscopy of mitophagic vesicles in BECs following a 2-hour 
exposure to MWCNTs. FCCP (5 μM), a mitochondrial uncoupling agent, was used as a 
positive control.  A) MWCNTs induced a significant increase in mitophagic vesicles which 
was attenuated by co-exposure with Mdivi-1, a mitophagy inhibitor. B) Pixel density analysis 
was used to quantify staining of mitophagic vesicles and normalize it to lysosomal staining 
for each of the 4 responding donors (BECs 2, 4, 6, and 8).  N = 4, ANOVA, Tukey post-hoc, 






Table 2.1 Demographical information for each donor (Bronchial Epithelial Cells BEC1-8).  
The study included a narrow age range (between 23 and 32 years) of donors to control for 
age-related mitochondrial heteroplasmy.  Donors were a mix of races (black, non-hispanic 
white, and Asian) and included 5 females and 3 males. 
 
 
 Age Gender Race 
BEC1 27 F Black 
BEC2 27 F Black 
BEC3 32 M Black 
BEC4 23 F Black 
BEC5 27 F Asian 
BEC6 28 M White 
BEC7 27 F White 


















Table 2.2 PrimePCR MIQE context sequences.  As the primer sequences used for the 
mitochondrial gene expression arrays are the proprietary information of BioRad 













































































CHAPTER 3: MITOCHONDRIAL RNA PROCESSING IN BRONCHIAL 
EPITHELIAL CELLS OF PATIENTS WITH SEVERE 
 INFLAMMATORY LUNG DISEASES 
 
Introduction 
Correlations between metabolic function and inflammatory lung diseases have been 
investigated previously55 (e.g. establishment of a link between obesity and asthma194).  Our 
laboratory has focused on the mitogenomic effects of inflammatory lung disease, particularly 
asthma and cystic fibrosis, and our results suggest a downregulation of mitochondrial genes 
in bronchial epithelial cells (BECs) obtained from donors with these diseases when compared 
to healthy (non-smoker) controls.  Concurrent with these gene expression changes is an 
increase in unprocessed mitochondrial RNA sequences and downregulated nuclear-encoded 
genes regulating RNA splicing in diseased cells, which may contribute to the impaired 
mitochondrial gene expression. 
In this chapter, we tested the hypothesis that chronic inflammatory lung diseases can 
damage mtDNA and cause persistent mitogenomic effects in BECs.  To test this, we 
compared mitogenomic endpoints in primary BECs isolated from the lungs of 12 human 
donors.  Four donors had fatal asthma (FA), 4 were cystic fibrosis (CF) lung transplants, and 
4 were accident victims with otherwise healthy lungs.  For comparisons to mild asthma, 
primary BECs derived from bronchoscopy of 8 healthy and 8 mildly-asthmatic human donors 




mitochondrial (mt)DNA and RNA extraction and oxygen consumption assays.  
Mitochondrial gene expression was analyzed by using QPCR arrays containing primers 
against the protein-coding mtDNA genes (as used in our previous work18) normalized to 
mitochondrial ribosomal subunit 16S.  We measured heteroplasmy and induction of 
mutations in mtDNA using Illumina next-gen ultradeep sequencing (Miseq).  The effects of 
disease state on mitochondrial function were measured by Seahorse extracellular flux assay, 
measuring oxygen consumption and extracellular pH.  A Nanostring array containing probes 
for nuclear-encoded mitochondrial signaling genes and unprocessed mitochondrial RNA 
segments (the “MitoString” probe set195) was used to compare RNA processing and 
nuclear/mitochondrial interactions between disease states.   
 
Materials and Methods 
Primary Cell Acquisition and Clinical Consent 
Primary bronchial epithelial cells (BECs) were collected from explants of lungs 
donated to the University of North Carolina’s Cystic Fibrosis Center.  Donor consent for the 
use of tissues in clinical research was obtained in writing, and followed protocols approved 
by the UNC Chapel Hill Intramural Research Board (IRB# 03-1396).  BECs were sourced 
from 4 donors having fatal asthma (FA), 4 from cystic fibrosis (CF) lung transplants, and 4 
from healthy organ donors following accidental injury.  Donors were age-matched between 
26 and 42 years and were non-smokers. 
Cell Culture and Conditions 
BECs were passaged in 75 cm2 vented T-flasks at 37°C with 5% CO2 in serum-free 




culture to prevent variability in differentiation from becoming a confounding factor in this 
study.  For all experiments, cells were used at passage 3 (P3) to ensure that non-epithelial 
cells were removed from the culture and that any observed effects were persistent outside the 
lung microenvironment.  Cultures received fresh media every 2 days and generally took 4-6 
days between each subpassage.  Subpassage of cell cultures was performed using 0.25% 
trypsin/EDTA solution (Sigma) and 2mg/ml soybean trypsin inhibitor (SBTI).   
QPCR and Primer Sequences 
BECs were harvested at 90% confluence for total RNA using the RNeasy 
columns/reagents and QiaCube automated isolation/purification device (Qiagen), according 
to manufacturer’s protocol.  RNA was converted to cDNA libraries using iScript reverse 
transcription kits (BioRad) containing oligo dT’s and randomized hexamers.  PCR Prime 
arrays (BioRad) were pre-loaded with primer pairs for all 13 mitochondrially-encoded 
protein-coding genes, plus 16S endogenous controls.  Amplicon context sequences for these 
arrays can be found in Chapter 2, Table 2.2.  SSO Advanced SYBR Green master mix was 
used as a reporter dye in a StepOne real-time sequencer (ABI Technologies).  Assays were 
measured over 40 cycles, denaturing at 95°C for 5 seconds and annealing at 60°C for 30 
seconds. 
Ultradeep mtDNA Sequencing 
Total DNA was harvested from BECs using a cell scraper in 4°C phosphate buffered 
saline (PBS).  Cell suspensions were lysed with protease K and DNA extracted using 
DNeasy Blood and Tissue columns and QiaCube automated isolation/purification device 




SequalPrep Long PCR kits with dNTPs and the following primer sequences, resulting in 
“short” (7626 bp) and “long” (9286 bp) mtDNA fragments: 
Long Fragment: 
forward-AAC CAA ACC CCA AAG ACA CC  
reverse-GCC AAT AAT GAC GTG AAG TCC 
Short Fragment: 
forward-TCC CAC TCC TAA ACA CAT CC 
reverse-TTT ATG GGG TGA TGT GAG CC 
Removal of nuclear DNA, dNTPs, polymerases, and other contaminants was 
performed using DNA Clean and Concentrator columns (Zymo) according to manufacturer 
instructions to prepare the mtDNA for sequencing.  Tagmentation of mtDNA (combined 
short and long fragments) was carried out using a Nextera DNA Library Prep kit (Illumina) 
according to the manufacturer’s instructions.  DNA samples were added to a 96-well thermal 
cycler plate with Amplicon Tagment Mix and Tagment DNA buffer from the kit and heated 
at 55°C for 5 minutes.  Libraries were then amplified with indexed adapters and Nextera 
PCR Master Mix, first denaturing at 72°C and then running 15 cycles of 95°C for 10 
seconds, 55°C for 30 seconds, and 72°C for 30 seconds.  AMPure XP magnetic beads 
(Illumina) were used to purify the resulting mtDNA libraries, according to manufacturer 
instructions.  AMPure beads were added to each sample and allowed to incubate at room 
temperature for 7 minutes on a magnetic plate to pellet the DNA/beads.  Supernatants were 
discarded and the bead pellets were washed twice with 80% ethanol, then allowed to air dry 
completely (approximately 10 minutes).  Purified DNA was resuspended in AMPure 




Sensitivity Analysis (Thermo-Fisher) and the Agilent Bioanalyzer.  Tagmented mtDNA 
samples were analyzed on a MiSeq next-generation ultradeep sequencer (NGS, Illumina).  
Heteroplasmy and variant calling for insertion/deletion mutations was performed as 
described in Chapter 2. 
Alignment and Variant Calling 
Read pairs were aligned using bowtie2, version 2.0.0-beta7, to an index composed of 
the human mitochondrial genome only, acquired from GenBank May 2015 (accession 
NC_012920).  The alignments were performed in “--local” mode using the “--sensitive-local” 
preset options to allow insertions and deletions relative to the reference, as well as clipping of 
ends extending beyond the edges of the artificially linearized reference sequence.  Fragment 
lengths of up to 10kb were allowed, as well as a single mismatch per seed alignment (-X 
10000, -N 1). 
 Variants were identified with a custom script, utilizing a method adapted from 
Hodgkinson, et al.174.  For each sample, depth per allele, per strand was determined, allowing 
a minimum base and alignment quality score of 20.  Indels relative to the reference were 
counted only in the case that both flanking bases’, and any inserted bases’ quality scores met 
or exceeded this threshold.  Additionally, the depth calculation for sites adjacent to or within 
homopolymer runs considered only reads traversing the entire repeat.  Sites with less than 
2000x coverage were not considered, and variants were required to be observed at a 
frequency of 1% or greater, with a plus to minus strand coverage ratio greater than 0.1 and 
less than 0.9.  The probability of observing each alternate allele by chance was calculated 
using a Poisson distribution, with an expected error rate of 0.01 for SNPs (derived from the 




al175.  These p-values were adjusted for multiple testing using the Benjamini and Hochberg 
FDR method, and a significance threshold of 0.05 was applied. 
NanoString Gene Expression Analysis 
Mitochondrial RNA expression was examined using the NanoString platform 
(www.nanostring.com) utilizing the “Mitostring” codeset2 that measures 149 endogenous 
and 8 housekeeping (HK) RNA’s.  For each sample, 100 ng total RNA was prepared as per 
the manufacturer’s instructions.  RNA expression was quantified on the nCounter Digital 
Analyzer and raw and adjusted counts were generated with nSolver software (v4.0).  Data 
were adjusted utilizing the manufacturer’s positive and negative experimental control probes 
and normalized to 2 HK genes (ALAS1 and HPRT).  The 2 selected HK genes had the lowest 
variability across all samples and spanned the count range of the dataset.  All samples passed 
nSolver’s initial QA/QC controls.  Data adjusted by nSolver were then imported into Partek 
(v7.0), log2-transformed and quantile-normalized for further QA/QC.  A 1-way ANOVA on 
experimental group was performed to determine differences in gene expression. 
Droplet Digital PCR 
 Oil-droplet digital PCR (ddPCR) was used to measure low-abundance unprocessed 
RNA transcripts in cDNA(diluted 1/100x)  from healthy and diseased BECs.  Droplets 
containing Evagreen (BioRad) master mix, primers spanning gene junctions (Table 3.2), and 
sample cDNA were generated using a BioRad Automated Droplet Generator, using duplicate 
wells for each sample in a 96-well plate.  Droplet plates were then sealed with aluminum and 
amplified in a C1000 Touch Thermal Cycler (BioRad), for 50x cycles of 95C for 10 sec and 
55C for 30 sec.  Once cooled to 4C, plates were then moved to a BioRad QX200 Droplet 




of cDNA copies per μl from FAM channel emission spectra, and these raw values were 
normalized to expression of a protein-coding mitochondrial gene transcript (MT-CO1). 
Extracellular Flux Assay 
An extracellular flux assay was used to determine differences in oxygen consumption 
rate (OCR) in BECs.  Cells from healthy, fatal asthmatic, and cystic fibrosis donors were 
seeded onto a 96-well Seahorse XF96 microplate in BEGM.  Cells were allowed to reach 
confluence, with fresh changes of medium every 2 days.  On the day of the assay, cells were 
washed 3 times with PBS and fed 180 μl/well of pre-warmed (37°C) Seahorse XF medium, 
consisting of XF Base medium with additional supplements of 1mM sodium pyruvate, 11 
mM D-glucose, and 2 mM L-glutamine, with the pH adjusted to 7.4 using NaOH and HCl.  
The sensor cartridge (following an overnight incubation in XF calibrant solution at 37°C and 
0% carbon dioxide) was loaded with reagents from the Seahorse Mito Stress Test: 2 uM 
oligomycin (20 ul of 20 uM per well), 2uM Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP, at 22 ul of 20 uM per well), and 0.5 uM 
rotenone/antimycin A (25 ul of 5 uM per well).  The Seahorse XFe96 extracellular flux 
instrument was programmed to take 3 measurements before and after the injection of each of 
the 3 compounds, with each measurement having taken approximately 8.7 seconds.  All 
reagents used for Seahorse XF analysis were obtained from Agilent. 
 
Results 
Mitochondrial Gene Expression Downregulated in Severe Lung Disease 
Expression of all 13 protein-coding mitochondrial genes was compared between 




measured in all genes but one (MT-ND4) with FA having an overall greater effect on gene 
expression than CF.  Subunits of NAD Dehydrogenase (Complex I) were most affected, as 2-
3 fold lower expression of these subunits was found in diseased cells. 
By contrast, a statistically significant effect on the expression of only 2 genes (MT-
ND1 and MT-ND4L), with a non-significant trend of downregulation in most others (Figure 
3.2) was found with the mild asthma donors.  As none of these genes were up/downregulated 
more than 2-fold compared to healthy BEC expression, mild asthma effects on mitochondrial 
gene expression may not be biologically meaningful, but suggest a progression in 
mitochondrial effects from mild to severe lung disease. 
Oxygen consumption decreased in BECs from severely diseased lungs 
 Depletion of extracellular oxygen was used as an indicator of mitochondrial function 
and was measured by Seahorse Extracellular Flux assay.  Downregulation in severe asthma 
and cystic fibrosis was coincident with decreased mitochondrial oxygen consumption, 
indicating that the gene expression changes in mitochondria have functional effects on cell 
metabolism (Figure 3.3).  Oxygen consumption rate (OCR) in diseased BECs was not 
significantly different from healthy BECs at baseline and following ATPase inhibition by 
oligomycin A.  However, uncoupled OCR was significantly impaired in diseased cells (1-
way ANOVA, p < 0.05 with Tukey multiple comparison correction), indicating a loss of 
reserve metabolic capacity.  Glycolytic oxygen consumption (following inhibition of 
Complex I by rotenone) was unaffected by disease state. 
Increase in BEC heteroplasmic minor allele frequency in severe lung disease 
 Heteroplasmic frequency of minor alleles in mtDNA was measured by ultradeep 




alleles unique to each disease state (mild asthma, FA, or CF) have been compiled in Table 
3.1.  Each variant’s FASTA sequence was entered into the MitoMaster tool in MitoMap 
(www.mitomap.org) to identify predicted haplotypes and any known pathologies associated 
with germline mutations196.  Each disease condition has at least 1 unique variant allele with 
known/published associated pathology, indicating that these minor alleles have potentially 
biologically significant effects on metabolic function. 
 Total heteroplasmic variant alleles were counted in each donor and normalized per 10 
kbp (Figure 3.4).  Despite the presence of potentially important variant alleles, the abundance 
of heteroplasmic sites in mild asthma was not statistically different from healthy BEC 
controls.  However, a small, yet statistically-significant, increase in heteroplasmy was found 
in both FA and CF (increasing by an average of approximately 1 heteroplasmic site per 10 
kbp), which suggests a progression from mild to severe lung disease (1-way ANOVA, 
p<0.05).   
Insertion/deletion mutations unchanged by disease state 
 The presence of indel mutations, relative to the hg19 reference sequence, in mild 
asthma and severe disease was also assessed by ultradeep sequencing (Figure 3.5).  Indel 
counts of all donors were averaged and normalized per 10 kpb.  While variant alleles flagged 
as indels were found in donors from all disease conditions (likely haplotype variability from 
the hg19 consensus), the total number of indels was not significantly different between 
conditions.  Indel counts varied between BECs derived from bronchoscopy (healthy vs mild 
asthma) and BECs derived from lung explants (healthy vs severe lung disease), with a nearly 




derived.  This increase may be due to the comparatively small cell yields from bronchoscopy 
resulting in a much higher number of cell doublings required for freezing at passage 1. 
No increase in mtDNA lesions detected 
 Lesions in mtDNA were measured by PCR reaction with fluorescent labeling, with 
the presence of lesions impeding the polymerase and decreasing fluorescence intensity.  
Emission intensities were used to calculate total lesions per 10 kbp of nucleic acid sample 
(Figure 3.6).  No statistically-significant increases in mtDNA lesions were detected in BECs 
from any disease condition relative to healthy BEC controls.  As heteroplasmic minor allele 
frequencies were slightly elevated in severe lung disease, the absence of persistent lesions 
may be indicative of translesion synthesis (TLS) and/or mitophagic turnover of damaged 
mtDNA.  These results also suggest that direct mtDNA damage is not primarily responsible 
for the gene expression changes.   
Upregulation of unprocessed mtRNA transcripts in fatal asthma 
 The MitoString probe set of 149 mitochondrial and nuclear RNA transcripts was used 
to assess the processing of mtRNA in BECs from donors with severe lung disease.  Probes 
which spanned mtRNA splicing junctions (between protein-coding and tRNA sequences, for 
example) were used in a NanoString instrument to probe for unprocessed RNA segments.  
We found that unprocessed mitochondrial gene transcripts were increased in CF and FA 
cells, and a much greater effect occurred in FA (Figure 3.7).  Hierarchical clustering found 
multiple nuclear-encoded genes regulating RNA splicing to have been downregulated in 
diseased cells, potentially contributing to the impaired mtRNA processing197 and reduced 
gene expression in mitochondria.  Unprocessed sequences which were significantly 




RNR2_TRNL1, rc_ND5_ND6, and TRNK_ATP8.  The differences in expression patterns 
between disease states was illustrated in a principal components analysis (Figure 3.8) which 
found that patterns of expression in CF vs healthy donors were not as pronounced as those in 
FA donor BECs. 
 These results were supported by droplet digital PCR (ddPCR) using probes against 
mtRNA gene junctions (Table 3.2).  The ddPCR instrument allows for detection of low-
abundance transcripts and was used to corroborate the NanoString results with a PCR-based 
measurement.  A statistically-significant increase in unprocessed mtRNA transcripts 
TRNF_RNR1 and TRNL1_ND1 was detected in FA compared to healthy BECs (2-way 
ANOVA, p<0.05 with Dunnet multiple comparison correction), though not in CF donor 
BECs.  A non-significant trend towards upregulation of other mtRNA gene junctions was 
found in FA donors (Figure 3.9). 
 
Discussion 
In this chapter, we investigated the effects of chronic inflammatory lung disease on 
the mitochondrial genome of airway BECs.  We hypothesized that the highly oxidative 
microenvironment of the chronically-inflamed airway would result in genotoxicity and 
heteroplasmy in BECs which would be detectable following their removal from the lungs.  
We utilized ultradeep sequencing to identify heteroplasmic variation in mtDNA sequences 
between BECs from healthy donors and those with mild asthma, fatal asthma, or cystic 
fibrosis.  We also measured de novo mutations (compared to the hg19 reference sequence), 




Our results suggest that mitochondrial gene expression is impaired in BECs from patients 
with cystic fibrosis or fatal asthma.  This effect was found after multiple passages following 
removal from the lung and leads to functional effects on oxygen consumption in these cells. 
However, changes in mtDNA sequence, heteroplasmic frequency, and lesions were minor 
and insufficient to explain the gene expression results.  We then measured mtRNA 
processing in diseased BECs using NanoString with the MitoString probe set.  A significant 
elevation in unprocessed mtRNA transcripts was found in diseased BECs compared to 
healthy controls, and this effect was more pronounced in fatal asthma.  We were able to 
support the NanoString results using ddPCR and gene junction-spanning primer sets, in 
which higher concentrations of unprocessed mitochondrial gene transcripts were found in 
BECs from fatal asthma.  The increase in unprocessed mitochondrial RNA in BECs from 
donors with chronic lung inflammation suggests that impaired mtRNA processing may have 
a role in impaired gene expression, similar to effects seen in Leigh Syndrome and PNPT1 
insufficiency198.   
The present study has several limitations which constrain the conclusions which can 
be drawn from it.  Sample sizes are small, with 4 donors per group for fatal asthma and cystic 
fibrosis, due to the scarcity of human BECs from patients with these conditions199.  This not 
only makes obtaining a population-representative sample size implausible, but also limits the 
number of studies which can be performed with any given sample.  Secondly, in vitro 
research alone cannot positively establish a mechanism of impaired mitochondrial RNA 
processing.  An animal model of fatal/severe asthma may replicate the disease conditions 
expected in a human lung, though it is not clear that severe human asthma can be fully 




would be necessary to recreate the mitochondrial RNA processing phenotypes we found in 
human samples.  Another variable is the added stress of in vitro growth, compared to in vivo, 
potentially resulting in mitochondrial dysfunction and impaired RNA processing in diseased 
cells where it otherwise would not201.  Measurement of unprocessed mRNA fragments and in 
vivo metabolic assays in animal models would be needed to rule out this possibility.  Finally, 
there remains a question of causality in this study, in which it is unclear whether the 
mitochondrial dysfunction is contributing to the development of inflammatory airway disease 
or whether the disease is causing the mitochondrial dysfunction (or both, as in a feedback 
loop).  Performing mitogenomic studies of non-lung cells/tissues from these patients would 
help to answer this question, though these materials were not available for this study.   
Despite these limitations, our work remains highly relevant and informative due to 
the use of primary cells isolated from human patients with inflammatory lung diseases.  As 
human fatalities resulting from asthma are rare, obtaining samples from these severe cases is 
difficult yet presents an opportunity to study the cellular effects contributing to patient 
decline in severe asthma. While our sample size is currently small, we believe this study may 
reveal an important causal link between chronic lung inflammation and persistent 








Figure 3.1 Mitochondrial gene expression in BECs from donors with severe lung disease, 
fatal asthma and cystic fibrosis. Most of the 13 mitochondrial protein-coding genes were 
downregulated in FA and CF donors compared to healthy donors.  Expression was 
normalized to 16S, a mitochondrial ribosomal subunit.  Significance determined by ANOVA, 


















Figure 3.2 Mitochondrial gene expression in BECs from donors with mild asthma, compared 
to healthy BECs. In contrast to severe disease, significant downregulation was only observed 
in ND1 and ND4L.  Expression was normalized to 16S, a mitochondrial ribosomal subunit.  
Significance determined by ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, following Tukey 



















Figure 3.3 Oxygen consumption rate (OCR, in pmol/min measured every 8 min) in BECs 
from healthy, fatal asthmatic, and cystic fibrosis donors, as measured by Seahorse 
Extracellular Flux (XF) assay.  Error bars represent standard error around the mean of 4 
combined donors per disease condition. *ANOVA p < 0.05, Tukey multiple comparison 














Figure 3.4 Heteroplasmic loci in mild asthma (A) and severe disease (B).   Heteroplasmic 
loci with 1% minor allele frequency or greater, compared to the hg19 reference sequence, 
were counted following ultradeep sequencing of mtDNA. Heteroplasmy counts are given per 
10k base pairs.  Incidence of heteroplasmy is significantly increased with severe 






Figure 3.5 Insertion/deletion mutations in mild asthma (A) and severe disease (B).   Indels 
compared to the hg19 reference sequence were counted following ultradeep sequencing of 
mtDNA. Indel counts are given per 10k base pairs.  No statistically-significant increases in 








Figure 3.6 Mitochondrial DNA lesions, per 10k base pairs, measured by PCR-based DNA 
damage assay.  No significant increases in mtDNA damage were observed in diseased cells 















Figure 3.7 Nanostring probes for gene junctions reveal an upregulation of unprocessed 
mitochondrial RNA segments (such as ND4_TRNH and TRNK_ATP8) in FA and CF donors 
compared to healthy donors.  The 22 genes which were significantly up/downregulated 
following a 1-way ANOVA (p < 0.05) are shown here following unsupervised hierarchal 






Figure 3.8 Principal component analysis (PCA) of the Nanostring results indicates a well-
defined separation of the 3 disease groups, with CF having less effect on mtRNA processing 
















Figure 3.9 Digital PCR of unprocessed mtRNA sequences. Impaired processing of mtRNA 
was found in fatal asthmatics, with significant upregulation of unprocessed RNR1 and ND1 



















































Table 3.1 MitoMap search results for all variant alleles found in mild asthma, fatal asthma, 
and cystic fibrosis donors examined in this study. 
 
Mild Asthma       
Position Reference Mutant  Gene Predicted Associated  
  Allele Allele Locus Haplotype Pathologies   
310 T C D-Loop U4a None found  
9010 G A ATPase6 M3b Unspecified neurological disorder 
4170 C T ND1 M12 None found  
16093 T C D-Loop H76a Cyclic Vomiting Syndrome 
6712 A T COI H2a None found  
16278 C T D-Loop H1 None found  
        
Fatal Asthma       
Position Reference Mutant  Gene Predicted Associated  
  Allele Allele Locus Haplotype Pathologies   
3010 G A 16S H1 Cyclic Vomiting Syndrome/Migraine 
16185 C T D-Loop R24 None found  
6349 C T COI H2a None found  
16035 G T D-Loop H2a None found  
214 A G D-Loop B4c None found  
        
Cystic Fibrosis       
Position Reference Mutant  Gene Predicted Associated  
  Allele Allele Locus Haplotype Pathologies   
3542 T C ND1 H2a None found  
1624 C T tRNA-V H2a Leigh Syndrome  
16147 C T D-Loop U6a None found  
4822 T C ND2 H2a None found  














Table 3.2 Primer sequences for droplet digital PCR detection of unprocessed mtRNA 
transcripts.  Primer pairs span gene junctions along the polycistronic mtRNA transcript and 
upregulation in expression of a gene junction indicates failed mtRNA post-transcriptional 
processing. 
 
Primer Name   5' to 3' Sequence   
TRNF_RNR1 Forward TGT AGC TTA CCT CCT CAA AGC A 
 Reverse AGG GTG AAC TCA CTG GAA CG 
TRNV_RNR2 Forward GCT TAA CAC AAA GCA CCC AAC 
 Reverse ACG GGT GTG CTC TTT TAG CTG 
TRNL1_ND1 Forward CC GGT AAT CGC ATA AAA CT 
 Reverse TAG ATG TGG CGG GTT TTA GG 
TRNM_ND2 Forward AAG GTC AGC TAA ATA AGC TAT CG 
 Reverse AAA AAT CAG TGC GAG CTT AGC 
TRND_CO2 Forward GAA AAA CCA TTT CAT AAC TTT GTC A 
 Reverse GGA AAA TGA TTA TGA GGG CG 
TRNK_ATP8 Forward TTA AGA GAA CCA ACA CCT CTT TAC A 
 Reverse GGG CAA TGA ATG AAG CGA ACA G 
TRNG_ND3 Forward CCG TTA ACT TCC AAT TAA CTA GTT TTG 
 Reverse TGT AGC CGT TGA GTT GTG GTA G 
TRNR_ND4 Forward AAC AAA ACG AAT GAT TTC GAC TC 
 Reverse TAA GAG GGA GTG GGT GTT GAG G 
TRNL_ND5 Forward CAG CTA TCC ATT GGT CTT AGG C 
 Reverse GGA TGC GAC AAT GGA TTT TA 
TRNE_ND6 Forward AAT AAC ACA CCC GAC CAC AC 













CHAPTER 4: CONCLUSIONS AND PERSPECTIVES 
 
Summary of Findings 
 In this dissertation, I have explored several mechanisms by which mitogenomic 
endpoints could be persistently altered by lung disease.  The original hypothesis was that 
chronic inflammation and oxidative lung injury would cause mtDNA damage in airway 
epithelial cells, and this damage would then lead to heteroplasmy and mitochondrial 
dysfunction.  The results of my work ran contrary to these expectations, as changes in 
heteroplasmic allele frequencies were either non-existent or minimally significant in the 
conditions I investigated.  Instead, I discovered previously uncharacterized mechanisms of 
mitochondrial stress that ultimately resulted in altered mitochondrial gene expression and 
cellular metabolic dysfunction. 
 In Chapter 2, I investigated the effect of nanomaterial exposure on the mitogenomics 
of primary human BECs from 8 healthy donors.  This experiment was an acute in vitro 
exposure model (lasting 5 days in submerged culture) which was intended to evaluate 
whether high, sub-cytotoxic, doses of nanoparticles with demonstrated genotoxicity could 
induce heteroplasmy within BECs.  MWCNTs, NG, nAg, and nCeO2 were tested for their 
ability to induce changes in mtDNA, including indel mutations, heteroplasmy, and 
mitochondrial gene expression.  Of these, only MWCNTs caused any consistent changes in 




mitochondrial genes.  This result was initially surprising on its own, because a 
downregulation would have been predicted by my hypothesis.  Both nAg and nCeO2 caused 
significant upregulation only in donor BEC2 (a 27yo black female), which is a another 
potentially interesting finding, suggesting there may be donor-specific susceptibility to 
nanoparticle exposure in general.  Because MWCNTs generated the only consistent response 
among multiple donors, this subgroup was the focus of later experiments.  I found that 
MWCNTs did not induce any lasting mutations or heteroplasmy, which was consistent with 
the lack of any downregulation of mtDNA expression.  However, the mitochondrial 
abundance per cell, as measured by separate flow cytometry experiments measuring SDHA 
staining and MitoTracker, was significantly decreased.  Further, mitochondrial function, 
measured by the extracellular flux assay of oxygen consumption, was significantly 
decreased, both basally and following uncoupling by FCCP.  Because MWCNTs appeared to 
cause mitochondrial damage, I hypothesized that the upregulation of mitochondrial genes 
may have been due to a compensatory biogenesis effect to replace lost mitochondrial mass.  
To test this, I used a dye-based mitophagy assay to stain mitophagic vesicles for visualization 
in a confocal microscope, 2 hours after MWCNT exposure.  I discovered that MWCNTs 
were inducing widespread mitophagy in exposed BECs, and that this effect could be 
inhibited by Mdivi-1, an inhibitor of the drp1 protein necessary for mitochondrial fission.  
While I did not find the nanoparticle-induced heteroplasmy I had originally expected, the 
capability of carbon nanotubes to generate metabolic dysfunction by inducing mitophagy in 
human cells was previously unknown.  Because MWCNTs are known to be genotoxic, it is 
possible that mtDNA damage still contributes to the loss of mitochondrial mass following 




damage mtDNA by mitophagy.  However, because all that is required to trigger mitophagy is 
an increase in mitochondrial inner-membrane permeability, the physical penetration of 
nanotubes into the mitochondrial lumen would, hypothetically, be sufficient by itself to cause 
the effects I observed in this study. I also acquired TEM images of MWCNTs physically 
intruding and depolarizing mitochondria in exposed cells, so the genotoxic potential of the 
MWCNTs may not be important for describing its effects on cellular metabolism. 
 In Chapter 3, I explored the concept of mitochondrial heteroplasmy in the context of 
chronic airway inflammation.  Instead of an acute toxicological study on healthy BECs, I 
assessed mitogenomic endpoints and metabolic function in BECs taken from human lungs 
with chronic inflammatory airway diseases.  Mild and fatal asthma, and cystic fibrosis, were 
compared to healthy BECs for mitochondrial gene expression, mtDNA sequencing, and 
oxygen consumption.  I found that mild asthma induced no significant changes in mtDNA 
heteroplasmy, mutations, or lesions, and that expression of mtDNA was downregulated 
significantly in 2 of the 13 protein-coding genes.  However, because there appeared to be a 
non-significant trend towards downregulated genes, I acquired BECs from 4 donors each of 
more severe lung inflammatory diseases: fatal asthma and cystic fibrosis.  Results from these 
severe disease donors were much more pronounced, with a 2 to 3- fold downregulation of 
nearly all mitochondrial genes.  Heteroplasmic loci, while significantly elevated statistically 
in severely-diseased donor BECs, was only increased by an average of 1 locus per donor.  
While these loci were found in the regulatory D-loop mtDNA region, they were inconsistent 
between donors and seemed unlikely to explain the reductions in gene expression on their 
own.  The frequencies of indel mutations and mtDNA lesions were not significantly changed 




not have been primarily responsible for the downregulation.  I then attempted a Nanostring 
analysis (using the MitoString probe set) to explore differences in mito-nuclear interactions 
between the disease states.  The probe set contained 149 mitochondrial and nuclear mito-
regulating genes, as well as precursor (unprocessed) RNAs and tRNAs.  Nanostring requires 
no amplification steps, thereby avoiding the addition of polymerase errors as a confounding 
variable.  I found that in diseased BECs, several mitochondrial gene junctions had failed to 
be properly spliced, resulting in the upregulation of unprocessed mtRNAs.  These results 
were supported by ddPCR measurement of mtRNA splicing junctions, consistent with 
upregulation in multiple unprocessed transcripts in FA. 
 
Potential Therapeutic Measures 
While there is now much supporting evidence for the importance of mtDNA damage, 
heteroplasmy, and gene expression in chronic inflammatory lung disease, the development of 
novel therapies which take advantage of this information remains in its infancy.  Small 
molecules which can regulate mitophagy in the lung have obvious potential as mtDNA-
targeted therapy, given that mitophagy is the natural process by which the cell conducts 
mtDNA turnover.  However, while induction of mitophagy by uncoupling agents (e.g., 
FCCP202) or other substances which generate mitochondrial stress (e.g., rapamycin203 or 
tomatine) is quick and effective, the toxicity of these substances may limit their therapeutic 
window204.  Induction of mitophagy is, by itself, hazardous to the cell and may require days 
of mitochondrial biogenesis to recover from205.  Nonetheless, this type of therapy has been 
implemented, with positive outcomes, in clinical cases for use against multiple cancers206-207 




Use of mitochondrial-targeted antioxidants is another potential avenue to mitigate 
mitogenomic damage because redox stress is a likely contributor to mtDNA lesions.  
Antioxidants, such as MitoTEMPO (Sigma Aldrich), with the ability to diffuse through lipid 
bilayers and accumulate in the mitochondrial lumen, can be used as scavengers of genotoxic 
superoxide radicals210-211.  While such treatments could hypothetically reduce mtDNA 
damage due to redox stress in the lung, the long-term adverse effects of repeated exposure to 
MitoTEMPO and similar antioxidants is poorly studied212, and so their utility against chronic 
inflammatory diseases is currently uncertain.  Moreover, such treatments would be strictly 
prophylactic, and by themselves would not address any existing mtDNA lesions or 
heteroplasmy. 
The impaired processing of mitochondrial RNA cells from fatal asthma and cystic 
fibrosis could be the result of several different mechanisms, and potential therapeutic 
measures would require a better understanding of why these diseases result in an increase in 
unprocessed mtRNA. One possibility is through the impaired function of ELAC2 or 
MRPP1/2, enzymes which are responsible for the post-transcriptional RNA processing in the 
mitochondrion.  Another possibility is a failure to degrade unprocessed mtRNA through the 
ATP-dependent RNA helicase SUPV3L1 (SUV3) and the G-rich sequence factor 1 (GRSF1) 
complex.  As these are nuclear-encoded proteins, their impaired function in chronic lung 
inflammation may be due to oxidative damage or epigenomic effects on nuclear DNA or 
simply downstream effects of inflammatory signaling.  Additional research is needed to 
determine what therapeutic measures, if any, would be appropriate for addressing the 





Open Questions and Future Research 
Mitogenomic damage and heteroplasmy are only recently being investigated as 
symptoms (or drivers) of inflammatory lung disease.  Consequently, there remain many 
unanswered questions needed to fully characterize the role of mitochondrial genomics in 
these diseases.  Much recent research has only been made possible through advances in 
ultradeep sequencing and measurement of real-time oxygen consumption, and it is certain 
that there is much left to discover in this emerging field. 
A question left largely unaddressed in the studies described in this dissertation is that 
of causality.  While there appear to be clear associations between mitogenomic damage and 
oxidative lung injury, the question of whether the injury is primarily generating the mtDNA 
damage or whether mtDNA heteroplasmy/sequence variants form a susceptible population is 
mostly unexplored29.  An approach to investigate this question would be to compare mtDNA 
heteroplasmy, mutations, and lesions in the bronchial epithelial cells as well as a non-lung 
tissue of patients with chronic inflammatory lung disease.  Determination of whether 
sequence variants in mtDNA exist throughout the somatic cells of a diseased donor could 
provide evidence that these variants conferred susceptibility to the disease120 or were simply 
the result of oxidative stress/genotoxicity in the lung78. 
Another important question is that of nuclear-mitochondrial signaling and its role in 
these diseases.  Most of the proteins regulating mitochondrial fission/fusion, mitophagy, 
biogenesis, and the majority of ETC complex subunits are encoded in the nuclear DNA, and 
while nuclear genotoxicity has been much more extensively studied in inflammatory lung 
disease, the unique interactions between nuclear and mitochondrial DNA are less 




requires enzymes encoded in the nucleus214.  The peptide humanin results from alternative 
RNA processing of the transcript which would otherwise encode the mitochondrial ribosomal 
subunit 16S215, and similar peptides (including 6 known small humanin-like peptides, 
SHLP1-6) have been identified in recent years216 and are known to have cytoprotective 
effects.  While the nuclear DNA encoding mtRNA processing is relatively well-protected in 
the nuclear envelope, the mitochondrial targets of those genes are more vulnerable.  A better 
understanding of the interaction between nucDNA and mtDNA is necessary for the 
development of more effective therapeutic interventions targeting mitogenomic damage in 
the lung. 
It is also critically important to know whether mtDNA damage in oxidative lung 
injury has the potential for greater systemic disease, apart from its role in 
exacerbating/prolonging pulmonary dysfunction caused by these conditions.  While impaired 
cellular metabolism in the lung epithelium is of concern, the possibility that mitogenomic 
damage could increase the risk of lung cancer217-218 or cause shock through systemic 
DAMPs219-220 would be much more dangerous.  For example, work by Ding et al221 has 
identified several mtDNA variants associated with an increased risk of lung cancer, 
particularly mutations in 235A/G and 324A/G within the D-loop. The risk of squamous cell 
carcinoma was increased by polymorphisms at loci 151C/T, 200A/G, 524C/CA, and 
16274G/A, whereas 16298T/C was associated with the risk of small cell lung cancer.  While 
the mechanisms for this are currently unclear, it is possible that, due to nuc/mtDNA 
crosstalk, mutations induced in mtDNA could affect the transcription or function of 




mechanisms by which mitogenomic damage in the lung can progress to more serious 
outcomes, as well as therapeutic targets to prevent this. 
While this work has thus far focused on the more recent developments in mtDNA 
damage-induced heteroplasmy and mitochondrial dysfunction in in the lung, it remains 
important to investigate the more traditional contributor to mtDNA disease: maternal 
inheritance.  Maternally-inherited mtDNA may have significant impacts on asthma.  A meta-
analysis by Lim et al222, that screened literature from 1966 to 2009, found that maternal 
asthma was a greater risk factor than paternal for predicting asthma in children.  Another 
study by Fu et al223 found downregulation of mitochondrial cytochrome oxidase III mRNA 
expression in asthmatic patients and concluded that serum IgE levels may be altered by 
mtDNA inherited by the mother.  At a minimum, the evidence that maternally-inherited 
mtDNA can influence asthma lends credibility to the hypothesis that somatic alterations in 
mtDNA could exacerbate inflammatory lung disease.  Studying the role for mtDNA in the 
progression of chronic lung inflammation is therefore of paramount importance for 




 While there remain unanswered questions and many avenues for further study, the 
results of my research suggest that multiple types of oxidative lung injury can have persistent 
effects on mitochondrial gene expression in human bronchial epithelial cells.  While I 




oxidative injury and mitochondrial gene expression, I instead found evidence for previously 
undescribed pathways (nanoparticle-induced mitophagy and impaired mtRNA processing) 
which could explain the gene expression findings. I also found that these mitogenomic 
effects impaired cellular metabolism, which could lead to an exacerbation and/or lasting 












APPENDIX I: SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
 
Gene Expression and Heteroplasmy in Nanographite Shape Control 
To determine the effect of MWCNT shape on mitochondrial gene expression, 
heteroplasmy, and insertion/deletion mutations, BECs were also exposed to mesoporous 
graphitized nanocarbon (nanographite, NG), a chemically-similar nanomaterial consisting of 
graphene sheets rather than tubes.  Nanographite was used at 12ug/ml and was found to be 
non-cytotoxic at this dose in our previous work.  NG was purchased from Sigma Aldrich (St. 
Louis, MO) and its purity was determined to be >99.95%, with only trace metals present, and 
particle size determined to be <500nm in diameter. Surface area was measured at 70m2/g 
with a 137Å average pore diameter.  Unlike MWCNTs, nanographite did not induce 
significant changes in expression of mitochondrial genes. It also was not capable of inducing 











Appendix 1, Figure 1 Mitochondrial gene expression following 5-day exposure to NG.  In 
contrast to MWCNTs, no changes in expression of mitochondrial genes were found in any 
donor, indicating that the effects seen from MWCNTs may be due to their high aspect ratio 













Appendix 1, Figure 2 Frequency of heteroplasmy as measured by ultra-deep sequencing.  
Heteroplasmies with greater than 10% alternate allele frequency (compared to hg19 
reference) were counted for each donor following treatment.  NG (at 12ug/ml) exposures 
were compared to the MWCNT and vehicle control exposures.  No statistically-significant 












Appendix 1, Figure 3 Frequency of indels as measured by ultra-deep sequencing.  Indel 
mutations (compared to hg19 reference) were counted for each donor following treatment.  
NG (at 12ug/ml) exposures were compared to the MWCNT and vehicle control exposures.  













Mitochondrial DNA Agarose Gels 
 Following long PCR amplification of the short and long mtDNA fragments using 
SequalPrep kits, fragments were run on 0.8% agarose gels (SeaKemp) to verify the presence 
of mtDNA product.  A single band corresponding to the size fragment amplified was 
observed for each sample, verifying the specificity of the SequalPrep amplification.  Samples 

















Appendix 1, Figure 4 High contrast images of mtDNA bands following electrophoresis.  
Long fragments and short fragments were run on separate gels. Only samples 1-8 (BEC1-
BEC8, respectively) were used for this study; samples 9-12 in the gel images were outside 















Darkfield Confocal Microscopy  
The use of a darkfield condenser with a confocal microscope to image light scattered 
by nano-scale particles within the cell was performed as described by EA Gibbs-Flournoy, et 
al224.  This method allowed for a qualitative assessment of the distribution of nanotubes 
within the BECs.  In control dispersion-vehicle BECs only the DAPI nuclear stain can be 
seen.  In MWCNT-treated BECs white scatter cones indicating the presence of light-
scattering particles were diffuse throughout the cell, though the nuclei themselves appeared 
















Appendix 1, Figure 5 Darkfield confocal imaging of intracellular MWCNT distribution.   
Orthogonal views show selected x- and y- sections of the confocal z-stack, demonstrating the 










Appendix 1, Figure 6 Additional electron micrographs of MWCNT fibers within the 









APPENDIX 2: NANOSILVER AND NANOCERIA RESULTS 
 
Nanomaterial Characterization 
Nano-silver (nAg) solutions were obtained from SilverLungs, LLC at approximately 
12 ppm.  Solutions consisted of ionic, uncoated silver and distilled water.  Inductively-
coupled plasma mass spectrometry (ICP-MS, Duke University) was used to verify >99% 
purity, with 30% found in the silver (I) oxide oxidation state.  Aggregates of ion-shedding 
silver particles were found by TEM imaging to be 5-10 nm in diameter. 
CeO2 was sourced from Meliorum Technologies and was found to be 10-30 nm in 
size and 194 nm in hydrodynamic diameter.  The CeO2 used in this study had a cubic 
crystalline structure and >99% purity (determined by XRD analysis), with irregular 
morphology. 
Treatment in Submerged Culture 
 Nanomaterials were dispersed in BEGM culture medium supplemented with sterile 
600 μg/ml bovine serum albumin (BSA) and 10 μg/ml 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) surfactant.  Control vehicle exposures used the supplemented 
medium without nanomaterials.  Prior to exposure, stock solutions of nAg (12 ppm) and 
CeO2 (2 mg/ml) were sonicated in a cup horn for 15 minutes (5 pulses of 3 minutes each) at 
100 amplitude to break up agglomerated materials, then diluted to treatment concentrations 
in dispersion vehicle at 1 ppm nAg, and 5 μg/ml CeO2.  While these concentrations were the 
highest non-cytotoxic doses we determined previously, we also verified cytotoxicity for this 




Appendix 2, Figure 1 Mitochondrial gene expression in BECs exposed to 1ppm nAg, as 
measured by QPCR.  Values are expressed as fold control (dispersion vehicle-treated) BECs, 
with each symbol representing the mean of 3 experimental replicates of a different donor (A).  
Of all donors samples, only BEC2 responded to nanosilver treatment (identified by p < 0.05 
on 2-way ANOVA).  This is illustrated in Figure (B), showing donor-specific patterns of 
up/downregulation when all genes from a given donor are combined.  Dotted lines indicate 
the standard deviation around the mean value for vehicle-treated controls (*p < 0.05, **p < 
























Appendix 2, Figure 2 Mitochondrial gene expression in BECs exposed to 5μg/ml CeO2, as 
measured by QPCR.  Values are expressed as fold control (dispersion vehicle-treated) BECs, 
with each symbol representing the mean of 3 experimental replicates of a different donor (A).  
As in nanosilver treatment, only BEC2 responded to nanoceria treatment (identified by p < 
0.05 on 2-way ANOVA).  This is illustrated in Figure (B), showing donor-specific patterns 
of up/downregulation when all genes from a given donor are combined.  Dotted lines indicate 
the standard deviation around the mean value for vehicle-treated controls (*p < 0.05, **p < 
























Appendix 2, Figure 3 Frequency of heteroplasmy as measured by ultra-deep sequencing.  
Heteroplasmies with greater than 10% alternate allele frequency (compared to hg19 
reference) were counted for each donor following treatment.  Following 5 days of exposure, 
no statistically-significant changes in heteroplasmy were observed from any of the studied 












Appendix 2, Figure 4 Frequency of insertion/deletion mutations as measured by ultra-deep 
sequencing.  Total indels (compared to hg19 reference) were counted for each donor 
following treatment.  Following 5 days of exposure, no statistically-significant changes in 













Appendix 2, Figure 5 Oxygen consumption rate (OCR) in BECs following 24-hour 
exposure to nanomaterials, as measured by Seahorse Extracellular Flux assay.  OCR 
measurements at all time points were normalized to total well protein measured after the 
assay.  Baseline OCR was significantly reduced in MWCNT-treated cells compared to 
controls, but not significant in nanosilver- and nanoceria- treated BECs.  No differences in 
non-mitochondrial respiration (following the addition of rotenone) were found in any 
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